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Summary of findings {#CD004773-sec1-0001}
===================

Summary of findings for the main comparisonAntifungal prophylaxis versus no antifungal prophylaxis for preventing cryptococcal disease in HIV‐positive people**Antifungal prophylaxis versus no antifungal prophylaxisPatient or population:** people who are HIV‐positive **Setting:** global **Intervention:** antifungal prophylaxis **Comparison:** no antifungal prophylaxis**OutcomesAnticipated absolute effects^\*^ (95% CI)Relative effect (95% CI)Number of participants (trials)Certainty of the evidence (GRADE)Risk with no antifungal prophylaxisRisk with antifungal prophylaxis**All‐cause mortality111 per 1000119 per 1000 (89 to 159)RR 1.07 (0.80 to 1.43)3220 (6 RCTs)⊕⊕⊝⊝ Low^a,b,c^Cryptococcal disease occurrence30 per 10009 per 1000 (5 to 15)RR 0.29 (0.17 to 0.49)5000 (7 RCTs)⊕⊕⊕⊝ Moderate^d,e^Mortality due to cryptococcal disease11 per 10003 per 1000 (1 to 9)RR 0.29 (0.11 to 0.72)3813 (5 RCTs)⊕⊕⊕⊝ Moderate^e,f^Clinical resistance of *Candida* species to fluconazole49 per 100046 per 1000 (28 to 77)RR 0.93 (0.56 to 1.56)1198 (3 RCTs)⊕⊕⊝⊝ Low^g,h^Microbiological resistance of *Candida* to fluconazole: surveillance sampling348 per 1000435 per 1000 (348 to 539)RR 1.25 (1.00 to 1.55)539 (3 RCTs)⊕⊕⊝⊝ Low^i,j^Treatment discontinuation259 per 1000262 per 1000 (236 to 293)RR 1.01 (0.91 to 1.13)2317 (4 RCTs)⊕⊕⊕⊝ Moderate^b^Any serious adverse event153 per 1000165 per 1000 (127 to 215)RR 1.08 (0.83 to 1.41)888 (4 RCTs)⊕⊕⊝⊝ Low ^b,c,k^Any adverse events320 per 1000342 per 1000 (281 to 415)RR 1.07 (0.88 to 1.30)2317 (4 RCTs)⊕⊕⊝⊝ Low^b,l^\***The risk in the intervention group** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI). **CI:** confidence interval; **RR:** risk ratio; **OR:** odds ratio; **ART:** antiretroviral therapy**GRADE Working Group grades of evidence** **High certainty:** we are very confident that the true effect lies close to that of the estimate of the effect **Moderate certainty:** we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different **Low certainty:** our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect **Very low certainty:** we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect[^2]

Background {#CD004773-sec1-0002}
==========

Description of the condition {#CD004773-sec2-0001}
----------------------------

Cryptococcal disease is an opportunistic infection that is common among people who are HIV‐positive with low cluster of differentiation 4 (CD4) cell counts. In 2014, the global prevalence was 6% ([@CD004773-bbs2-0050]). It is a leading cause of morbidity and mortality, both before and after initiation of anti‐retroviral therapy (ART) in patients with low CD4 counts ([@CD004773-bbs2-0042]). It is mostly caused by infection with *Cryptococcus neoformans. Cryptococcus gattii* is responsible in some cases. Patients may present with meningitis, pneumonia, or in some rare cases, cutaneous, ophthalmic, or prostatic lesions ([@CD004773-bbs2-0053]). Cryptococcal meningitis is the commonest presentation of HIV‐related cryptococcal disease in adults. It is the leading cause of meningitis in adults in sub‐Saharan Africa, and accounts for 15% of HIV‐related deaths globally ([@CD004773-bbs2-0050]). The case fatality rate in sub‐Saharan Africa ranges from 35% to 65%, compared with 10% to 20% in most high‐income countries ([@CD004773-bbs2-0045]). While high‐income countries have seen considerable reduction in the incidence of cryptococcal meningitis following increased access to ART ([@CD004773-bbs2-0047]), low‐income countries have not experienced the same decline ([@CD004773-bbs2-0055]; [@CD004773-bbs2-0056]; [@CD004773-bbs2-0059]). This may be attributed to late diagnosis of HIV and delays in starting ART in these settings ([@CD004773-bbs2-0043]). In some settings, over 50% of HIV‐positive people and presenting with cryptococcal meningitis are ART‐experienced ([@CD004773-bbs2-0052]).

There are various diagnostic tools available for the detection of cryptococcal disease. Cryptococcal meningitis can be diagnosed through cerebrospinal fluid (CSF) microscopy, culture, or cryptococcal antigen detection. A positive cryptococcal antigen (CrAg) test does not confer diagnosis, as HIV‐positive people with advanced disease can be CrAg‐positive weeks to months before the development of cryptococcal meningitis. India ink microscopy of CSF is the commonest technique, but has reduced sensitivity if the fungal burden is low. CSF culture, considered the gold standard, has a higher yield than India ink, but may also have poorer sensitivity with low fungal burdens. CSF cryptococcal antigen testing is highly sensitive and specific for cryptococcal meningitis, and is available as a point‐of‐care rapid test. Blood culture, or serum or plasma cryptococcal antigen testing, can be used to detect disseminated infection ([@CD004773-bbs2-0036]). Pulmonary cryptococcal disease can be detected through cryptococcal antigen testing of bronchoalveolar fluid; however, the sensitivity of this test is low, and the definitive diagnosis is made through histopathology, cytopathology, or culture of respiratory specimens or biopsies.

Description of the intervention {#CD004773-sec2-0002}
-------------------------------

Prophylaxis for the prevention of opportunistic infections, such as *Pneumocytis* (PJP) is an integral component of HIV care, and has been shown to reduce HIV‐associated mortality among people with low CD4 counts ([@CD004773-bbs2-0058]). When primary prophylaxis for cryptococcal disease is administered, typically, antifungals are used. A previous version of this Cochrane Review showed that primary prophylaxis with fluconazole or itraconazole reduced the incidence of cryptococcal disease, but had no effect on mortality ([@CD004773-bbs2-0061]).

Oral fluconazole is well‐absorbed and well‐tolerated, without significant adverse events ([@CD004773-bbs2-0046]). It is commonly used for secondary prophylaxis of cryptococcal meningitis after successful treatment, to prevent relapse ([@CD004773-bbs2-0057]). Long periods of monotherapy for primary or secondary prophylaxis may increase the risk of cryptococcal resistance to fluconazole ([@CD004773-bbs2-0034]; [@CD004773-bbs2-0037]), especially in patients whose CD4 cell counts are falling ([@CD004773-bbs2-0044]). A systematic review showed that primary fluconazole prophylaxis may result in increased risk of colonization with susceptible dose‐dependent or resistant yeasts; however, no effect was seen on the risk of resistant systemic fungal infection ([@CD004773-bbs2-0035]). The concern remains that with widespread use of antifungal prophylaxis, resistant fungal strains will render antifungals ineffective, resulting in refractory or relapsed cases of cryptococcal meningitis in HIV‐positive people.

Oral itraconazole does not absorb as well as fluconazole, and its bioavailability is markedly influenced by gastric contents. Erratic absorption with the capsule formulation, and high rates of gastrointestinal intolerance with the oral solution, have led to decreased use of this antifungal agent in recent years ([@CD004773-bbs2-0049]). In addition, drug interactions mediated through the cytochrome P450 enzyme system may further limit the use of itraconazole as part of a multi‐drug regimen ([@CD004773-bbs2-0048]).

How the intervention might work {#CD004773-sec2-0003}
-------------------------------

There are two broad approaches to preventing cryptococcal disease. The first method (primary prophylaxis) consists of treating all those with a low CD4 count with prophylactic antifungals, while simultaneously initiating ART. This prevents cryptococcal disease during the period of immune recovery. The second method of controlling cryptococcal disease involves screening and pre‐emptive treatment. This method has been recommended by the World Health Organization (WHO), and relies on the ability to detect cryptococcal antigen in the blood. Patients who are HIV‐positive, and have severe disease with low CD4 counts, are tested for the presence of cryptococcal antigen in blood; if positive, they are investigated for cryptococcal disease, and treated with antifungals ([@CD004773-bbs2-0057]).

Both methods have advantages and disadvantages. Primary prophylaxis has been shown to be effective at reducing the incidence of cryptococcal meningitis at a population level, but is less cost effective ([@CD004773-bbs2-0022]). Prior to this review, the use of prophylactic antifungals in cryptococcal antigen negative patients with low CD4 counts was only recommended by the WHO if a prolonged delay in ART initiation was likely. This recommendation was based on the lack of a consistent survival benefit associated with primary prophylaxis, costs associated with providing prophylaxis to a large number of people, and concerns over drug resistance and congenital anomalies ([@CD004773-bbs2-0057]).

The focus of this review was solely on the effects of primary prophylaxis with an antifungal agent. However, these are not, and should not, be considered mutually exclusive interventions.

The optimal CD4 count level at which primary antifungal prophylaxis should be initiated is unclear. Different studies have reported initiating treatment at \< 50 cells/µL ([@CD004773-bbs2-0022]), \< 100 cells/µL ([@CD004773-bbs2-0002]; [@CD004773-bbs2-0022]), \< 200 cells/µL ([@CD004773-bbs2-0006]), and \< 300 cells/µL ([@CD004773-bbs2-0009]), with varying cost‐effectiveness.

Why it is important to do this review {#CD004773-sec2-0004}
-------------------------------------

The previous published version of this review showed that primary antifungal prophylaxis with either itraconazole or fluconazole was effective in reducing the incidence of cryptococcal disease in adults with advanced HIV disease. However, the effect on overall mortality was unclear ([@CD004773-bbs2-0061]). Since the review\'s publication, a number of new, relevant trials have been published. Another review, which included observational studies in addition to randomized controlled trials (RCT), similarly concluded that primary antifungal prophylaxis could prevent cryptococcal meningitis, but not reduce all‐cause mortality ([@CD004773-bbs2-0054]). However, the scope of the review was limited to the adult population, and publications in English, in peer‐reviewed journals, with an outdated literature search.

In order to provide updated high‐quality evidence, we restricted our studies to RCTs, included paediatric populations, and non‐English publications, and conducted searches of the grey literature. The outputs of this review can contribute to the formulation of future guideline recommendations for the prevention of cryptococcal disease in adults and children who are HIV‐positive.

Objectives {#CD004773-sec1-0003}
==========

To assess the efficacy and safety of antifungals for the primary prevention of cryptococcal disease in adults and children who are HIV‐positive.

Methods {#CD004773-sec1-0004}
=======

Criteria for considering studies for this review {#CD004773-sec2-0005}
------------------------------------------------

### Types of studies {#CD004773-sec3-0001}

We included RCTs.

### Types of participants {#CD004773-sec3-0002}

Adults and children who are HIV‐positive, with low CD4 cell counts, without a current or prior diagnosis of cryptococcal disease.

### Types of interventions {#CD004773-sec3-0003}

#### Interventions {#CD004773-sec4-0001}

Triazole antifungals, used as primary prophylaxis to prevent fungal infections. We considered drugs within this class approved for clinical use, such as itraconazole, fluconazole, voriconazole, posaconazole, and isavuconazole.

#### Control {#CD004773-sec4-0002}

Placebo or no antifungal intervention.

### Types of outcome measures {#CD004773-sec3-0004}

#### Primary outcomes {#CD004773-sec4-0003}

All‐cause mortality: number of deaths from any cause/number randomized

#### Secondary outcomes {#CD004773-sec4-0004}

Cryptococcal disease:number of HIV‐positive people diagnosed/number randomizedincluding episodes of: antigenaemia, meningitis, or pneumonia during the follow‐up perioddiagnosis of antigenaemia: serum cryptococcal antigen test, blood culturediagnosis of meningitis: CSF India ink staining, CSF culture, CSF cryptococcal antigen testdiagnosis of pneumonia: culture, histopathology, or cytopathology of respiratory specimensDeaths due to cryptococcal disease: number of deaths attributed to a diagnosis of cryptococcal meningitisAdherence: number categorized as adherent by authors/number randomizedCryptococcal antifungal drug resistance: number categorized as resistant by authors/number randomizedInfections caused by *Candida* species resistant to the prophylactic antifungal drug: number with infections by resistant *Candida*/number randomizedTreatment discontinuation: number discontinuing regimen due to adverse events, patient choice, pregnancy, or for any other reason. This was only assessed in trials with placebo control arms.Adverse events:number with any reported adverse event/number randomizedin addition, severe (grades 3 to 5) hepatotoxicity (elevated ALT and AST), anaemia, rash, diarrhoea, nausea, and vomiting (categorized according to the Division of AIDS Table for Grading severity of Adult and Paediatric adverse events) will be evaluated as the number with severe adverse events/number randomized for each of these events ([@CD004773-bbs2-0038]).

Search methods for identification of studies {#CD004773-sec2-0006}
--------------------------------------------

We attempted to identify all relevant studies, regardless of language or publication status. We included all studies that addressed one or more of our outcomes.

### Electronic searches {#CD004773-sec3-0005}

We searched the following databases on 31 August 2017: the Cochrane Central Register of Controlled Trials (CENTRAL; 2017, issue 8), published in the Cochrane Library; MEDLINE PubMed; Embase OVID, and CINAHL EBSCOHost, using the search strategies in [Appendix 1](#CD004773-sec2-0015){ref-type="app"}.

We also searched the WHO International Clinical Trials Registry Platform (WHO ICTRP; [www.who.int/ictrp/en/](www.who.int/ictrp/en/)) and ClinicalTrials.gov (<https://clinicaltrials.gov/ct2/home>) on 31 August 2017, to identify ongoing trials.

### Searching other resources {#CD004773-sec3-0006}

#### Grey literature {#CD004773-sec4-0005}

We actively searched for grey literature, by contacting researchers in the field and searching for publications regardless of language.

We searched abstracts from the Conference on Retroviruses and Opportunistic Infections (CROI) and the International AIDS (IAS) conferences. We searched conference outputs from 2015, 2016, and 2017.

#### Reference lists {#CD004773-sec4-0006}

We checked the reference lists of all studies identified by the above methods for other potentially relevant studies. We also searched the reference lists and included studies of other systematic reviews.

#### Correspondence {#CD004773-sec4-0007}

We contacted researchers working in the field for unpublished and ongoing trials.

Data collection and analysis {#CD004773-sec2-0007}
----------------------------

### Selection of studies {#CD004773-sec3-0007}

Two review authors (AA and SJ) independently screened the titles and abstracts of the search results to identify studies relevant to this review. We resolved disagreements through consultation with the third review author (IEW). We retrieved full‐text articles of potentially eligible trials. We included studies that met the predefined inclusion criteria. We resolved disagreements by discussion with the third review author.

### Data extraction and management {#CD004773-sec3-0008}

Two review authors (AA and SJ) independently extracted data from the included trials, using a standardized data extraction form, which we created and piloted. For each trial, we extracted the study design, risk of bias, participant characteristics (age, gender, ethnicity, baseline CD4+ T cell count and viral load, use of ART, time to ART, cryptococcal antigen status, endemicity of cryptococcus), trial setting, interventions (antifungal type, dose, and duration), duration of follow‐up, treatment discontinuations, adverse events, and reported outcomes.

We resolved disagreements in data extraction through consultation with the third review author (IEW). One author entered all the extracted data into Review Manager 5 ([@CD004773-bbs2-0051]). Another review author independently checked the entered data for accuracy. We contacted authors of primary trials for missing data.

### Assessment of risk of bias in included studies {#CD004773-sec3-0009}

Two review authors independently assessed the risk of bias for each included study, using the Cochrane 'Risk of bias\' assessment tool ([@CD004773-bbs2-0040]). We resolved disagreements through consultation with the third review author. We contacted trial authors for clarification when the risk of bias was unclear. We summarized the results of the risk of bias for each included trial in the 'Risk of bias\' tables.

### Measures of treatment effect {#CD004773-sec3-0010}

We measured the treatment effect for dichotomous outcomes using risk ratios (RR). We calculated 95% confidence intervals (CI) for all outcomes. We performed meta‐analysis where there were sufficient combinable data.

### Unit of analysis issues {#CD004773-sec3-0011}

We analysed the data at the level of the individual.

### Dealing with missing data {#CD004773-sec3-0012}

We performed all analyses on an intention‐to‐treat basis, using the total number of participants randomized as the denominator.

### Assessment of heterogeneity {#CD004773-sec3-0013}

We assessed heterogeneity by visual inspection of the forest plots for CIs overlap, and by using the Chi² test for heterogeneity. We quantified the heterogeneity using the I² statistic. We used the approach set out in the *Cochrane Handbook for Systematic Reviews of Interventions* for statistical tests of heterogeneity. We interpreted I² in the context of (i) magnitude and direction of effects and (ii) strength of evidence for heterogeneity (e.g. P value from the Chi² test, or a CI for I²). We classified heterogeneity as defined in the *Cochrane Handbook for Systematic Reviews of Interventions* ([@CD004773-bbs2-0040]):

0% to 40%: might not be important30% to 60%: may represent moderate heterogeneity50% to 90%: may represent substantial heterogeneity75% to 100%: considerable heterogeneity

We interrogated possible sources of heterogeneity, using subgroup analysis. Where we were unable to explain significant heterogeneity through subgroup analysis, we considered this when we assessed certainty of evidence with the GRADE criteria.

### Assessment of reporting biases {#CD004773-sec3-0014}

No analysis included more than 10 trials, so we were unable to assess for publication bias.

### Data synthesis {#CD004773-sec3-0015}

We analysed the data using Review Manager 5 ([@CD004773-bbs2-0051]). We used the random‐effects model for all meta‐analyses, as we considered the different studies to be estimating different, yet related, intervention effects ([@CD004773-bbs2-0040]). Where considerable unexplained heterogeneity was detected, we did not pool the results.

### Subgroup analysis and investigation of heterogeneity {#CD004773-sec3-0016}

We investigated potential sources of heterogeneity by performing subgroup analyses for all‐cause mortality and cryptococcal disease outcomes on the following.

CD4+ threshold for initiation of prophylaxisCrAg status at baselineTiming of ART initiationType of ARTType of antifungal medication

### Sensitivity analysis {#CD004773-sec3-0017}

We included all randomized trials in the meta‐analysis, regardless of their risk of bias.

We had intended to conduct sensitivity analyses for the primary outcome by excluding trials with a high or unclear risk of bias for the following.

Attrition (\> 20%)Sequence generationAllocation concealment

#### Assessing the certainty of the evidence {#CD004773-sec4-0008}

We evaluated the certainty of the evidence using the GRADE approach. We generated 'Summary of findings\' tables using GRADEpro GDT ([@CD004773-bbs2-0039]).

Results {#CD004773-sec1-0005}
=======

Description of studies {#CD004773-sec2-0008}
----------------------

See [Characteristics of included studies](#CD004773-sec2-0018){ref-type="sec"}; [Characteristics of excluded studies](#CD004773-sec2-0019){ref-type="sec"}; [Characteristics of studies awaiting classification](#CD004773-sec2-0020){ref-type="sec"}.

See [Figure 1](#CD004773-fig-0001){ref-type="fig"}: Study flow diagramFigure 1Study flow diagram.

### Results of the search {#CD004773-sec3-0018}

We retrieved 1069 records from our searches conducted between 1 January 1980 and 31 August 2017, using the terms in our search strategy in [Appendix 1](#CD004773-sec2-0015){ref-type="app"}. We identified 3 additional records through other sources. After removing duplicates, we identified 1045 records, which we screened for relevance against our inclusion criteria. We identified 41 records for full‐text screening; of these, we included nine randomized controlled trials (RCT) in 17 reports. The selection process is depicted in [Figure 1](#CD004773-fig-0001){ref-type="fig"}.

### Included studies {#CD004773-sec3-0019}

We included nine RCTs (17 records). See the '[Characteristics of included studies](#CD004773-sec2-0018){ref-type="sec"}\' tables.

We also summarized key characteristics of these studies in [Table 3](#CD004773-tbl-0003){ref-type="table"}, to aid interpretation of the data.Table 1Key characteristics of included studies**Study IDCountryNumber randomizedAge (years)CD4 threshold(cells/µL)Triple ART regimenInterventionTime to ARTExcluded CrAg +veCrAG status at baseline**[@CD004773-bbs2-0001]Thailand129Mean 33 (range 22 to 58)\< 200NoItraconazole 200 mg daily + CTXNRNoNR[@CD004773-bbs2-0002]Thailand90Range: 20 to 53\< 100NoFluconazole 400 mg weeklyNRYesCrAG‐ve:\
90/90[@CD004773-bbs2-0003]USA829Median 38 (range: 19 to 71)\< 150NoFluconazole 200 mg three times per weekNRNoNR[@CD004773-bbs2-0004]Uganda, Zimbabwe, Malawi, Kenya1805Median 36 (IQR 29 to 42)\< 100YesEnhanced prophylaxis:\
fluconazole 100 mg daily + CTX + INH daily + immediate albendazole + 5 days of azithromycin5 days (2 to 8)NoCrAG+ve: 133/1781[@CD004773-bbs2-0005]USA295Median 36 to 37\< 150NoItraconazole 200 mg dailyNRNoNR[@CD004773-bbs2-0006]Uganda1519Mean 36\< 200YesFluconazole 200 mg 3 times per week11 weeks (median; IQR 7 to 17 weeks); fluconazole 82 days; placebo 87 daysYesCrAG‐ve:\
1519/1519[@CD004773-bbs2-0007]USA62NR\< 350UnknownFluconazole 200 mg dailyNRNoNR[@CD004773-bbs2-0008]USA323Mean 37\< 300NoFluconazole 200 mg weeklyNRNoNR[@CD004773-bbs2-0009]Australia, Canada, South Africa, UK374Mean 38 (SD 8)\< 300NoItraconazole 200 mg dailyNRNoNR[^3]

#### Design {#CD004773-sec4-0009}

We included nine RCTs, with a total of 5426 participants. Two trials were conducted in Thailand ([@CD004773-bbs2-0001]; [@CD004773-bbs2-0002]), four in the USA ([@CD004773-bbs2-0003]; [@CD004773-bbs2-0005]; [@CD004773-bbs2-0007]; [@CD004773-bbs2-0008]), one in Uganda ([@CD004773-bbs2-0006]), and two were multi‐centre trials conducted in Uganda, Zimbabwe, Malawi, and Kenya ([@CD004773-bbs2-0004]), and Australia, Canada, South Africa, and the UK ([@CD004773-bbs2-0009]).

#### Participants {#CD004773-sec4-0010}

Most trials included both adults and adolescents, older than 13 years. One trial included adolescents over 15 years ([@CD004773-bbs2-0006]). One trial also included children older than five years ([@CD004773-bbs2-0004]).

Six trials did not report on the cryptococcal antigen (CrAg) status of their participants at baseline ([@CD004773-bbs2-0001]; [@CD004773-bbs2-0003]; [@CD004773-bbs2-0005]; [@CD004773-bbs2-0007]; [@CD004773-bbs2-0008]; [@CD004773-bbs2-0009]). [@CD004773-bbs2-0002] and [@CD004773-bbs2-0006] reported on the CrAg status of their participants at baseline, but excluded the CrAg‐positive patients. [@CD004773-bbs2-0004] reported on the CrAg status of participants at baseline, but did not exclude the CrAg‐positive patients.

Full inclusion and exclusion criteria are presented in the '[Characteristics of included studies](#CD004773-sec2-0018){ref-type="sec"}\' table.

#### Interventions {#CD004773-sec4-0011}

Six trials randomly assigned HIV‐positive participants to the antifungal study drug or placebo ([@CD004773-bbs2-0001]; [@CD004773-bbs2-0002]; [@CD004773-bbs2-0005]; [@CD004773-bbs2-0006]; [@CD004773-bbs2-0008]; [@CD004773-bbs2-0009]). Two studies randomized participants to continuous administration of antifungal prophylaxis or antifungals, as needed for the treatment of candidiasis ([@CD004773-bbs2-0003]; [@CD004773-bbs2-0007]). [@CD004773-bbs2-0004] assigned participants randomly to either standard prophylaxis for *Pneumocystis jiroveci* pneumonia (PJP) with trimethoprim‐sulfamethoxazole or an enhanced prophylaxis package consisting of 12 weeks of fluconazole (100 mg once a day), one dose of albendazole 400 mg, five days of azithromycin (500 mg once a day), 12 weeks of trimethoprim--sulfamethoxazole (trimethoprim 160 mg once a day and sulfamethoxazole 800 mg once a day), isoniazid 300 mg once a day, and pyridoxine 25 mg once a day for 12 weeks.

The choices and doses of antifungal used included itraconazole 200 mg daily ([@CD004773-bbs2-0001]; [@CD004773-bbs2-0005]; [@CD004773-bbs2-0009]), fluconazole 100 mg daily ([@CD004773-bbs2-0004]), fluconazole 200 mg daily ([@CD004773-bbs2-0007]), fluconazole 200 mg three times per week ([@CD004773-bbs2-0003]; [@CD004773-bbs2-0006]), fluconazole 200 mg weekly ([@CD004773-bbs2-0008]), and fluconazole 400 mg weekly ([@CD004773-bbs2-0002]).

Five included studies did not report if participants received co‐trimoxazole prophylaxis ([@CD004773-bbs2-0002]; [@CD004773-bbs2-0003]; [@CD004773-bbs2-0005]; [@CD004773-bbs2-0007]; [@CD004773-bbs2-0008]). Seventy‐five percent of participants in the treatment arm and 65% of participants in the placebo arm received co‐trimoxazole prophylaxis in [@CD004773-bbs2-0009]. One study reported that participants were offered co‐trimoxazole according to national guidelines ([@CD004773-bbs2-0006]). All participants in two trials received standard co‐trimoxazole prophylaxis ([@CD004773-bbs2-0001]; [@CD004773-bbs2-0004]).

Participants in the [@CD004773-bbs2-0004] and [@CD004773-bbs2-0006] trials were all anti‐retroviral therapy (ART)‐naïve at the start of follow‐up, and then received current standard ART triple therapy, initiated during the trial. Participant therapies in the [@CD004773-bbs2-0004] trial initiated ART at a median of five days, as would be expected under the current standard of care. Participants in the [@CD004773-bbs2-0006] study initiated ART at a median of 11 weeks. Five trials included participants that were on a mix of a non‐current standard ART regimen and no ART at baseline ([@CD004773-bbs2-0001]; [@CD004773-bbs2-0003]; [@CD004773-bbs2-0005]; [@CD004773-bbs2-0008]; [@CD004773-bbs2-0009]). HIV‐positive participants in [@CD004773-bbs2-0002] were all ART‐naïve at baseline, but they did not report which ART regimen they initiated. One trial did not report the ART status of its participants ([@CD004773-bbs2-0007]).

#### Outcome measures {#CD004773-sec4-0012}

Seven studies reported death as an outcome ([@CD004773-bbs2-0001]; [@CD004773-bbs2-0002]; [@CD004773-bbs2-0003]; [@CD004773-bbs2-0004]; [@CD004773-bbs2-0005]; [@CD004773-bbs2-0006]; [@CD004773-bbs2-0009]); we included six of these studies in our analysis. [@CD004773-bbs2-0004] reported all‐cause mortality; however, the co‐interventions used in this study, as described in [Table 3](#CD004773-tbl-0003){ref-type="table"}, could possibly have confounded any effect measured. Therefore, we did not include this study in our meta‐analysis for this outcome. The CD4 cell count thresholds for initiation of antifungal prophylaxis varied from \< 100 cells/µL to \< 300 cells/µL. Duration of follow‐up varied from 22 weeks to 42 months.

Seven studies reported the incidence of cryptococcal disease ([@CD004773-bbs2-0001]; [@CD004773-bbs2-0002]; [@CD004773-bbs2-0003]; [@CD004773-bbs2-0004]; [@CD004773-bbs2-0005]; [@CD004773-bbs2-0006]; [@CD004773-bbs2-0009]). Six studies measured cryptococcal disease occurrence, and used standard prophylaxis, consisting solely of an antifungal or placebo as an adjunct to standard care.

Five studies reported mortality due to cryptococcal disease ([@CD004773-bbs2-0001]; [@CD004773-bbs2-0002]; [@CD004773-bbs2-0004]; [@CD004773-bbs2-0005]; [@CD004773-bbs2-0006]). In these studies, there was variable reporting of the method of diagnosis of death due to cryptococcal disease. [@CD004773-bbs2-0004] measured cryptococcal disease occurrence and used enhanced prophylaxis, which included co‐interventions, as described in [Table 3](#CD004773-tbl-0003){ref-type="table"}. We did not deem these co‐interventions to be active on mortality due to cryptococcal disease, and so included this study in the pooled estimate.

Only [@CD004773-bbs2-0001] reported adherence to antifungal prophylaxis.

Four studies reported clinically defined *Candida* resistance in patients enrolled in trials ([@CD004773-bbs2-0001]; [@CD004773-bbs2-0003]; [@CD004773-bbs2-0007]; [@CD004773-bbs2-0008]). [@CD004773-bbs2-0001] compared Itraconazole to placebo, while [@CD004773-bbs2-0003], [@CD004773-bbs2-0007], and [@CD004773-bbs2-0008] compared fluconazole to placebo. We identified four studies that reported microbiologically‐defined resistance in *Candida* species isolated from patients enrolled in trials ([@CD004773-bbs2-0003]; [@CD004773-bbs2-0005]; [@CD004773-bbs2-0007]; [@CD004773-bbs2-0008]).

Four studies reported discontinuation of antifungal prophylaxis compared to placebo for any reason, and adverse events ([@CD004773-bbs2-0001]; [@CD004773-bbs2-0005]; [@CD004773-bbs2-0006]; [@CD004773-bbs2-0009]).

### Excluded studies {#CD004773-sec3-0020}

We excluded 22 studies after assessing the full‐text articles (see '[Characteristics of excluded studies](#CD004773-sec2-0019){ref-type="sec"}\' table).

#### Studies awaiting classification {#CD004773-sec4-0013}

We were unable to retrieve the full‐text reports of two studies to assess them for inclusion ([@CD004773-bbs2-0033], [@CD004773-bbs2-0032]).

Risk of bias in included studies {#CD004773-sec2-0009}
--------------------------------

We have presented the 'Risk of bias\' summary, which represents the review authors\' judgements about each risk of bias item for each included study in [Figure 2](#CD004773-fig-0002){ref-type="fig"}. We have summarized our findings for each domain below:Figure 2'Risk of bias\' summary: review authors\' judgements about each 'Risk of bias\' item for each included study

### Allocation {#CD004773-sec3-0021}

Computer‐generated randomization lists were used by [@CD004773-bbs2-0001]; [@CD004773-bbs2-0004]; and [@CD004773-bbs2-0009]. Random lists were generated using permuted blocks in [@CD004773-bbs2-0006]; [@CD004773-bbs2-0007]; and [@CD004773-bbs2-0008]. Methods for sequence generation were not explicitly stated in [@CD004773-bbs2-0003] and [@CD004773-bbs2-0005]. No methods for sequence generation were described for [@CD004773-bbs2-0002].

There was adequate concealment of treatment allocation in three of the nine trials ([@CD004773-bbs2-0001]; [@CD004773-bbs2-0004]; [@CD004773-bbs2-0006]). The remaining six did not record any method of allocation concealment.

### Blinding {#CD004773-sec3-0022}

We judged all nine trials to be free of the risk of performance bias, as all the participants received either the study medication or matching placebo. [@CD004773-bbs2-0004] was an open label trial, however, we judged our main outcomes to be objective assessments, and therefore not prone to performance bias.

We judged two of the nine trials as having unclear risk of detection bias ([@CD004773-bbs2-0003]; [@CD004773-bbs2-0008]).

### Incomplete outcome data {#CD004773-sec3-0023}

We judged [@CD004773-bbs2-0007] as having high risk of attrition bias, because a disproportionate number of participants in the intervention and control groups were excluded from the trial, based on death within three months of enrolment.

[@CD004773-bbs2-0005] and [@CD004773-bbs2-0002] were assessed as having unclear risk of attrition bias, because neither trial recorded any loss to follow‐up data.

The remaining six trials were judged as having low risk of attrition bias.

### Selective reporting {#CD004773-sec3-0024}

We assessed the risk of bias from selective outcome reporting to be unclear in [@CD004773-bbs2-0002], as the authors did not report loss to follow‐up, drop out rates, or adverse events in detail. The other eight trials were assessed at low risk.

### Other potential sources of bias {#CD004773-sec3-0025}

We assessed the risk of bias as high in the [@CD004773-bbs2-0007] study, because baseline characteristics and baseline ART status were not described. Four trials were judged as having unclear risk, because there was insufficient information available to make an assessment on whether the funding received from pharmaceutical companies impacted the study design or analyses ([@CD004773-bbs2-0001]; [@CD004773-bbs2-0002]; [@CD004773-bbs2-0005]; [@CD004773-bbs2-0009]). We judged four trials at low risk of other potential sources of bias ([@CD004773-bbs2-0003]; [@CD004773-bbs2-0004]; [@CD004773-bbs2-0006]; [@CD004773-bbs2-0008]).

Effects of interventions {#CD004773-sec2-0010}
------------------------

See: [Table 1](#CD004773-tbl-0001){ref-type="table"}

### Primary outcomes {#CD004773-sec3-0026}

#### All‐cause mortality {#CD004773-sec4-0014}

Antifungal prophylaxis had no consistent effect on all‐cause mortality (risk ratio (RR) 1.07, 95% CI 0.80 to 1.43; six trials, 3220 participants; [Analysis 1.1](#CD004773-fig-00101){ref-type="fig"}). We could not include data for this outcome from the most recent trial, which initiated ART a mean of five days after screening, as there were co‐interventions in the intervention arm that would have confounded the effect on mortality ([@CD004773-bbs2-0004]).

##### Subgroup analyses {#CD004773-sec5-0001}

There was little difference in pooled effect estimates when we subdivided all‐cause mortality by: CD4 threshold for prophylaxis (I² statistic = 0%; [Analysis 1.2](#CD004773-fig-00102){ref-type="fig"}), baseline CrAG status (I² statistic = 0%; [Analysis 1.3](#CD004773-fig-00103){ref-type="fig"}), time‐to‐initiation of ART (I² statistic = 0%; [Analysis 1.4](#CD004773-fig-00104){ref-type="fig"}), ART regimens (I² statistic = 0%; [Analysis 1.5](#CD004773-fig-00105){ref-type="fig"}), or type of antifungal drug (I² statistic = 0%; [Analysis 1.6](#CD004773-fig-00106){ref-type="fig"}).

### Secondary outcomes {#CD004773-sec3-0027}

#### Cryptococcal disease occurrence {#CD004773-sec4-0015}

We excluded unconfirmed, suspected cases of cryptococcal disease from our analysis. [@CD004773-bbs2-0004] measured cryptococcal disease occurrence, and used enhanced prophylaxis, which included co‐interventions described in [Table 3](#CD004773-tbl-0003){ref-type="table"}. We did not deem these co‐interventions to be active on cryptococcal disease, so included this study in the pooled estimate.

The seven studies that measured cryptococcal disease identified 91 cases. Most of the studies did not report the source of the cryptococcal infection, simply referring to invasive cryptococcal disease. All 10 cases in [@CD004773-bbs2-0002] were confirmed cases of cryptococcal meningitis; [@CD004773-bbs2-0009] reported one case of cryptococcal pneumonia and one case of cryptococcal meningitis. [@CD004773-bbs2-0006] confirmed 11 cases of cryptococcal meningitis, five participants with invasive cryptococcal disease and positive blood cultures, and three participants who became CrAg‐positive after starting prophylaxis. [@CD004773-bbs2-0004] reported 32 new cases of cryptococcal infection: 22 cases of cryptococcal meningitis, and one case of cryptococcal fungaemia in the standard prophylaxis arm, and nine cases of cryptococcal meningitis in the enhanced prophylaxis arm.

Meta‐analysis showed a large reduction in the risk of developing cryptococcal disease in those who received antifungal prophylaxis. Participants on antifungal prophylaxis were 71% less likely to develop cryptococcal disease than those receiving placebo or standard care (RR 0.29, 95% CI 0.17 to 0.49; seven trials, 5000 participants; [Analysis 1.7](#CD004773-fig-00107){ref-type="fig"}). Benefit of antifungal prophylaxis was seen consistently across the included studies, although this was not statistically significant at a 95% level of confidence in four of the studies.

##### Subgroup analyses {#CD004773-sec5-0002}

There was no clear difference in effect estimates when we subgrouped cryptococcal disease occurrence by: CD4 threshold for prophylaxis (I² 0%; [Analysis 1.8](#CD004773-fig-00108){ref-type="fig"}), ART regimen (I² statistic = 0%; [Analysis 1.9](#CD004773-fig-00109){ref-type="fig"}), or type of antifungal drug (I² 0%; [Analysis 1.10](#CD004773-fig-00110){ref-type="fig"} ). Subgrouping by time‐to‐initiation of ART showed a similar benefit of prophylaxis across all subgroups, with a small amount of heterogeneity (I² statistic = 36.9%; [Analysis 1.11](#CD004773-fig-00111){ref-type="fig"}). There was no clear difference between subgroups by baseline CrAG status (I² statistic = 0%; [Analysis 1.12](#CD004773-fig-00112){ref-type="fig"}). Proportionally fewer participants who were CrAg‐negative at baseline went on to develop cryptococcal disease (regardless of treatment arm) compared to CrAg‐positive cases. Few participants and one study contributed data to the baseline CrAg‐positive subgroup analysis ([@CD004773-bbs2-0004]).

#### Cryptococcal‐specific mortality {#CD004773-sec4-0016}

People taking antifungal prophylaxis were less likely to die from cryptococcal disease (RR 0.29, 95% CI 0.11 to 0.72; five trials, 3813 participants; [Analysis 1.13](#CD004773-fig-00113){ref-type="fig"}).

No clear difference was seen in studies that excluded participants who tested CrAG‐positive, and those on current standard ART regimens (one nucleoside reverse transcriptase inhibitor and two non‐nucleoside reverse transcriptase inhibitors).

#### Adherence {#CD004773-sec4-0017}

[@CD004773-bbs2-0001] (129 participants) reported no significant difference in adherence between participants receiving antifungals and placebo. Ninety‐two per cent of those receiving antifungals adhered to the regimen, while 85% of those receiving placebo adhered.

#### Cryptococcal antifungal drug resistance {#CD004773-sec4-0018}

We did not identify any studies that reported cryptococcal antifungal resistance.

#### Infections caused by *Candida* species resistant to the prophylactic antifungal drug triazole {#CD004773-sec4-0019}

#### (a) Clinical resistance {#CD004773-sec4-0020}

[@CD004773-bbs2-0008] compared fluconazole to placebo for the prevention of candidiasis. Two open label trials compared the continuous use of fluconazole prophylaxis for symptomatic treatment of clinical *Candida* disease ([@CD004773-bbs2-0003]; [@CD004773-bbs2-0007]). Clinical resistance was largely defined as participants who developed *Candida* disease that did not respond to treatment with fluconazole; the exact definition varied between studies, as described in [Table 4](#CD004773-tbl-0004){ref-type="table"}. We subgrouped the results of this analysis by antifungal therapy.Table 2Clinically defined resistance to fluconazole and itraconazole**Description of studies2 X 2 tableStudy IDAims of studyDefinition of clinical resistanceProphylaxis givenIntervention receivedNumber of participants with clinical disease resistant to fluconazoleNumber of participants randomizedClinically defined resistance (episodes of clinical resistance per number of patients randomised): fluconazole**[@CD004773-bbs2-0003]To compare fluconazole to standard care for the prevention of *Candida* infections.Clinical endpoint defined as persistent or refractory candidiasis\*Fluconazole 200 mg three times weeklyContinuous fluconazole18413Standard care18416[@CD004773-bbs2-0007]To compare fluconazole to standard care for the prevention of *Candida* infections.Clinical resistance was defined as the presence of resistant isolates (MIC \> 16 µg/mL) that affected response to therapyFluconazole 200 mg dailyContinuous fluconazole216Standard care528[@CD004773-bbs2-0008]To compare fluconazole to placebo for prevention of mucosal candidiasis in HIV‐positive women.Clinical resistance not definedFluconazole 200 mg once weeklyFluconazole6162Placebo + Standard care7161**Clinically defined resistance (episodes of clinical resistance per number of patients randomised): itraconazole**[@CD004773-bbs2-0001]To compare Itraconazole prophylaxis to placebo for the prevention of deep fungal infectionsClinical resistance defined as candidiasis that did not respond to treatment\*Itraconazole 200 mg dailyItraconazole163Placebo + Standard care066[^4]

##### Subgroup analyses {#CD004773-sec5-0003}

Neither fluconazole prophylaxis (RR 0.93, 95% CI 0.56 to 1.56; three trials, 1198 participants; [Analysis 1.14](#CD004773-fig-00114){ref-type="fig"}) nor itraconazole prophylaxis (RR 3.14, 95% CI 0.13 to 75.69; one trial, 129 participants; [Analysis 1.14](#CD004773-fig-00114){ref-type="fig"}) showed a clear effect on the risk of developing *Candida* disease clinically resistant to the antifungal agent.

#### (b) Microbiological resistance {#CD004773-sec4-0021}

Three studies monitored resistance by taking surveillance cultures obtained from mucosal swabs, and reporting all strains of *Candida* resistant to fluconazole ([@CD004773-bbs2-0003]; [@CD004773-bbs2-0007]; [@CD004773-bbs2-0008]). [@CD004773-bbs2-0003] and [@CD004773-bbs2-0007] reported resistance in oropharyngeal swabs, and [@CD004773-bbs2-0008] reported results from vaginal swabs. One study only reported *Candida albicans* isolates ([@CD004773-bbs2-0005]). [@CD004773-bbs2-0005] used itraconazole, and reported both resistance to itraconazole and cross‐resistance to fluconazole, from swabs of any mucosa, from participants with clinical disease. We defined resistance to fluconazole as a minimum inhibitory concentration (MIC) \> 16 µg/mL. All studies reported this. [@CD004773-bbs2-0008] reported participants with a MIC \> 16 µg/mL as 'dose‐dependent susceptible\'. They reported absolute resistance as MIC \> 64 µg/mL. For this analysis, we combined participants with these results to form an aggregate number of events with MIC \> 16 µg/mL ([Table 5](#CD004773-tbl-0005){ref-type="table"}). There was marked qualitative heterogeneity between studies that reported on this outcome, as sampling methods, antifungal drug, and *Candida* species detected differed markedly between [@CD004773-bbs2-0005] and the remaining studies. As a result, we chose not to pool estimates across all three studies.Table 3Microbiologically defined resistance of *Candida* to fluconazole**Description of studies2 X 2 tableStudy IDStudy aimsType of isolateOrganism reportedIntervention receivedNumber of participants with at least 1 isolate resistant to fluconazole (MIC, \> 16 µg/mL)Number of participants with at least one sample where *Candida* was isolatedMicrobiologically defined resistance of *Candida* to fluconazole (number of patients with at least one resistant isolate): fluconazole received**[@CD004773-bbs2-0008]To compare fluconazole to placebo for prevention of mucosal candidiasis in HIV‐positive womenVaginal mucosal surveillance cultures taken 3 monthlyAll *Candida* species combinedFluconazole2988Placebo + Standard care2179[@CD004773-bbs2-0003]To compare fluconazole to standard care for the prevention of *Candida* infectionsSurveillance swab obtained at end of the studyAll *Candida* species combinedContinuous fluconazole50110Standard care79218[@CD004773-bbs2-0007]To compare fluconazole to standard care for the prevention of *Candida* infectionsIsolates obtained from clinical disease and 3 monthly surveillance swabsAll *Candida* species combinedContinuous fluconazole916Standard care1328**Microbiologically‐defined resistance of *Candida* to fluconazole (number of patients with at least one resistant isolate): itraconazole received, cross‐resistance to fluconazole reported**[@CD004773-bbs2-0005]To compare Itraconazole to placebo for the prevention of deep fungal infections (including cryptococcal disease)Vaginal and oesophageal mucosal isolates from clinical disease occurrences*C. albicans* only (Other species not reported)Itraconazole9/40\* patients had isolates reported as 'not susceptible\'40Placebo + Standard care2/55\* patients had isolates reported as 'not susceptible\'55[^5]

##### Subgroup analyses {#CD004773-sec5-0004}

Among the three studies using fluconazole prophylaxis and surveillance sampling, antifungal prophylaxis was found to increase the risk of developing microbiological resistance to fluconazole in all *Candida* species (RR 1.25, 95% CI 1.00 to 1.55; three trials, 539 participants; [Analysis 1.15](#CD004773-fig-00115){ref-type="fig"}). In the subgroup, which included one study in which itraconazole prophylaxis was used and samples were obtained from clinical disease, we found that antifungal prophylaxis increased the risk of developing microbiological cross‐resistance to fluconazole among *C. albicans* species (RR 6.19, 95% CI 1.41 to 27.10; one trial, 95 participants; [Analysis 1.15](#CD004773-fig-00115){ref-type="fig"}; [@CD004773-bbs2-0005]).

#### Treatment discontinuation {#CD004773-sec4-0022}

Four studies reported the discontinuation of antifungal prophylaxis compared to placebo for any reason ([@CD004773-bbs2-0001]; [@CD004773-bbs2-0005]; [@CD004773-bbs2-0006]; [@CD004773-bbs2-0009]). The reasons included serious adverse events, hepatotoxicity, pregnancy, use of contraindicated medications (such as rifampicin), and patient decision ([Table 6](#CD004773-tbl-0006){ref-type="table"}). We found no clear difference between those who discontinued antifungal prophylaxis compared to placebo (RR 1.01, 95% CI 0.91 to 1.13; four trials, 2317 participants; [Analysis 1.16](#CD004773-fig-00116){ref-type="fig"}).Table 4Reasons for discontinuation of antifungal prophylaxis**Treatment discontinuation (cause)Antifungal groupPlacebo group**[@CD004773-bbs2-0001] (N = 129)Access disallowed medications^a^3 (2.3%)3 (2.3%)Adverse events2 (1.6%)1 (0.7%)Hepatotoxicity1 (0.7%)1 (0.7%)Patient choice14 (11%)9 (6.9%)[@CD004773-bbs2-0005] (N = 295)Adverse events13 (4.4%)5 (1.7%)Patient choice27 (9.1%)36 (12%)[@CD004773-bbs2-0006] (N = 1519)Loss to follow‐up31 (2%)19 (1.3%)Patient choice11 (0.7%)4 (0.3%)Safety concerns59 (3.8%)59 (3.8%)[@CD004773-bbs2-0009] (N = 374)Access disallowed medications^a^15 (4%)3 (0.8%)Adverse event31 (8.3%)29 (7.8%)Hepatotoxicity2 (0.5%)3 (0.8%)Patient choice33 (8.8%)46 (12%)Pregnancy0 (0%)1 (0.3%)Other37(9.9%)42 (11%)[^6]

#### Adverse events {#CD004773-sec4-0023}

We excluded [@CD004773-bbs2-0004] from the analysis of adverse events, as unpicking the effects of the co‐interventions delivered in this trial was not possible.

#### (a) Serious adverse events {#CD004773-sec4-0024}

Four studies reported serious adverse events ([@CD004773-bbs2-0001]; [@CD004773-bbs2-0002]; [@CD004773-bbs2-0005]; [@CD004773-bbs2-0009]). These were measured as the number of patients experiencing at least one serious adverse event. One study reported no adverse events in either group ([@CD004773-bbs2-0002]). All studies were conducted before 2004, and as such, the participants were on a mix of older anti‐retroviral drugs, described in [Table 3](#CD004773-tbl-0003){ref-type="table"}. There was no clear difference in the occurrence of serious adverse events between participants receiving antifungal prophylaxis and those receiving placebo. (RR 1.08, 95% CI 0.83 to 1.41; four trials, 888 participants; [Analysis 1.17](#CD004773-fig-00117){ref-type="fig"})

#### (b) Any adverse event {#CD004773-sec4-0025}

Four studies reported any adverse events ([@CD004773-bbs2-0001]; [@CD004773-bbs2-0005]; [@CD004773-bbs2-0006]; [@CD004773-bbs2-0009]).Three out of the four studies were conducted before 2004, and as such, the participants were on a mix of older anti‐retroviral drugs, described in [Table 3](#CD004773-tbl-0003){ref-type="table"}. Adverse events were measured as the number of patients experiencing at least one adverse event. There was no clear difference in the occurrence of adverse events between participants receiving antifungal prophylaxis and those receiving placebo (RR 1.07, 95% CI 0.88 to 1.30; 4 trials; 2317 participants; [Analysis 1.18](#CD004773-fig-00118){ref-type="fig"}).

No clear difference was found between groups for any of the most commonly reported adverse events ([Analysis 1.19](#CD004773-fig-00119){ref-type="fig"}).

Diarrhoea (RR 1.31, 95% CI 0.32 to 5.29; 2 trials, 424 participants)Abdominal pain (RR 0.91, 95% CI 0.56 to 1.46; 2 trials, 1814 participants)Nausea (RR 0.97, 95% CI 0.64 to 1.47; 2 trials, 1814 participants)Rash (RR 1.03, 95% CI 0.56 to 1.9; 4 trials, 2317 participants)

Discussion {#CD004773-sec1-0006}
==========

Summary of main results {#CD004773-sec2-0011}
-----------------------

See [Table 1](#CD004773-tbl-0001){ref-type="table"}.

Nine trials, enrolling 5426 participants, met the inclusion criteria of this Cochrane Review.

Antifungal primary prophylaxis alone may make little or no difference to all‐cause mortality (low‐certainty evidence). For cryptococcal‐specific outcomes, prophylaxis probably reduces the risk of developing cryptococcal disease (moderate‐certainty evidence), and probably reduces deaths due to cryptococcal disease (moderate‐certainty evidence). It may make no clear difference to the risk of developing clinically‐resistant *Candida* disease (low‐certainty evidence); however, there may be an increased risk of having *Candida* resistant to fluconazole isolated by surveillance cultures (low‐certainty evidence). Antifungal prophylaxis was generally well‐tolerated, with no clear difference in the risk of needing to discontinue antifungal prophylaxis compared with placebo (moderate‐certainty evidence), and no clear difference in the risk of having any adverse event (low‐certainty evidence) or a serious adverse event (low‐certainty evidence).

### Potential benefits of antifungal prophylaxis {#CD004773-sec3-0028}

Antifungal prophylaxis probably reduces the risk of developing cryptococcal disease. It also probably reduces the risk of dying from cryptococcal disease.

### Potential harms of antifungal prophylaxis {#CD004773-sec3-0029}

Antifungal prophylaxis is well tolerated, with no clear difference in the occurrence of adverse events, and probably no clear difference in treatment discontinuations. There may be an increased risk of developing fluconazole resistant *Candida* species, although this may not translate to disease resistant to treatment. In the absence of cryptococcal antigen (CrAg) screening programmes and high CrAg prevalence, primary prophylaxis could under‐treat CrAg‐positive people who are HIV‐positive with high titres and subclinical meningitis. Itraconazole potentially interacts with common first‐line antiretrovirals (tenofovir, efavirenz) rendering it less suitable for widespread use compared to fluconazole, where there are no interactions with current first line antiretrovirals ([@CD004773-bbs2-0041]).

Overall completeness and applicability of evidence {#CD004773-sec2-0012}
--------------------------------------------------

We included nine trials that evaluated the efficacy and safety of interventions for preventing cryptococcal infection in HIV‐positive people. Four of these trials were conducted in low‐ and middle‐income countries, while the remaining five were conducted in high‐income countries. All participants were adults, even though several studies included children and adolescents in eligibility criteria.

Several studies included in this review were older and less relevant to the contemporary HIV experience, due to changes in antiretroviral therapy (ART) treatment regimens and timing of ART initiation in recent years. Only two trials included participants who received currently recommended triple ART ([@CD004773-bbs2-0004]; [@CD004773-bbs2-0006]), and in only one of these was ART initiated within one to two weeks of HIV diagnosis, as would be the current practice, particularly in patients with low CD4 cell counts ([@CD004773-bbs2-0004]). In addition, three studies used itraconazole prophylaxis, which is less commonly used, due to substantial drug interactions ([@CD004773-bbs2-0001]; [@CD004773-bbs2-0005]; [@CD004773-bbs2-0009]). [@CD004773-bbs2-0004] evaluated a combination of interventions that included antifungals, antibiotics, and anthelmintics, compared with standard prophylaxis for pneumocystis using only co‐trimoxazole. Despite the finding that several studies did not represent the current HIV care experience, the protective effect of prophylaxis was consistent across all study populations, including those receiving the current standard of HIV care.

Two studies excluded CrAg‐positive patients prior to randomization ([@CD004773-bbs2-0002]; [@CD004773-bbs2-0006]). One study reported baseline CrAg status after trial completion ([@CD004773-bbs2-0004]). Among CrAg‐negative participants, antifungal prophylaxis continued to show a protective effect. However, there were far fewer occurrences of cryptococcal disease overall among those who were CrAg‐negative at baseline, compared to those who were CrAg‐positive.

We found no trials that reported on resistance of *Cryptococcus* isolates, and this is an important gap in our understanding of the adverse effects of antifungal prophylaxis.

There was some evidence that antifungal prophylaxis may increase the number of resistant *Candida* species in surveillance samples; however, it is unclear if this translates to clinically meaningful *Candida* resistance, as no clear effect was demonstrated on the risk of developing clinically resistant *Candida* disease. However, the certainty of the evidence contributing to these analyses was low, making it difficult to draw firm conclusions on the impact of antifungal prophylaxis on *Candida* resistance.

The data on adverse events from these trials were graded as low quality, and as a result, we should also interpret the finding of no clear difference between treatment arms with caution. However, moderate‐quality evidence suggested that treatment discontinuation did not clearly differ between study arms, suggesting that adverse events may in fact not differ between the groups.

### Certainty of the evidence {#CD004773-sec3-0030}

We assessed the certainty of the evidence using the GRADE approach and presented our findings in the [Table 1](#CD004773-tbl-0001){ref-type="table"}. Three of the included studies were designed as open label studies. We did not consider this biased the outcomes measured, as our primary outcome, and most of the secondary outcomes, were objectively measured. Certainty ranged from moderate to low across all the reported outcomes. Reasons for downgrading included: the majority of participants not receiving the current standard of care relating to type of ART, and time from diagnosis to initiation, indirectness related to the subjective assessment of mortality due to cryptococcal disease, few events, unclear grading of serious adverse events, and unexplained substantial heterogeneity related to the assessment of adverse events. Many of the trials we found were older and less relevant to current HIV care; we considered this in our approach to GRADEing indirectness.

Potential biases in the review process {#CD004773-sec2-0013}
--------------------------------------

We minimized biases in the conduct of this review by adhering to the standard methodology described in *Cochrane Handbook for Systematic reviews of Interventions*. We conducted a comprehensive literature search with no language restrictions. Two authors independently scanned the search results for potentially eligible studies. Two review authors independently assessed full‐text articles of potentially eligible trials, and two review authors independently extracted data from the nine included trials.

We recognized that there were limitations and potential biases in measuring mortality due to cryptococcal disease, due to the risk of misdiagnosis. However, we chose to include this outcome to give a better reflection of the effect of the intervention on cryptococcal disease. We took this into account in our assessment of the certainty of the evidence.

Resistance to fluconazole is one of the main concerns and criticisms of antifungal prophylaxis, but microbiological resistance detected in surveillance cultures did not necessarily translate to clinical disease; however, the review would have been somewhat incomplete if we did not present all the evidence that was available on this issue. Again, this was taken into account in our assessment of the certainty of the evidence.

We further amended our inclusion criteria to include studies with co‐interventions. We minimized the confounding effect of these co‐interventions by only including trials with outcomes where the co‐interventions were considered to have minimal or no impact on the outcome being measured. For example, [@CD004773-bbs2-0004] reported a reduction in all‐cause mortality; however, there were important co‐interventions that would have had an effect on mortality, so these data were not included in the analysis for this outcome.

These differences are detailed in the [Differences between protocol and review](#CD004773-sec1-0017){ref-type="notes"} section.

Agreements and disagreements with other studies or reviews {#CD004773-sec2-0014}
----------------------------------------------------------

The findings from this review were consistent with those of previous published reviews, which both showed that antifungal prophylaxis may have made little or no difference to all‐cause mortality, but reduced the occurrence of cryptococcal disease ([@CD004773-bbs2-0061]; [@CD004773-bbs2-0054]). However, the findings from this review are more relevant to current HIV populations.

One study included in the [@CD004773-bbs2-0061] review did not meet our inclusion criteria. We also included two studies published after the [@CD004773-bbs2-0061] review ([@CD004773-bbs2-0004]; [@CD004773-bbs2-0006]). Furthermore, we considered outcomes related to resistance in trials looking at prevention of *Candida* infection, which were not included in the [@CD004773-bbs2-0061] review ([@CD004773-bbs2-0003]; [@CD004773-bbs2-0007]; [@CD004773-bbs2-0008]) .

Authors\' conclusions {#CD004773-sec1-0007}
=====================

Primary prophylaxis with either fluconazole or itraconazole probably reduces the risk of developing cryptococcal disease. Prophylaxis also probably reduces the risk of death due to cryptococcal disease, however, this may not have translated to a reduction in all‐cause mortality in the trials identified. Clinicians and policy makers will have to consider the benefit of providing antifungal prophylaxis in the context of cryptococcal disease prevalence, cost, consistent drug supply, and the availability of cryptococcal antigen (CrAg) screening in their setting. Antifungal primary prophylaxis could be considered a part of differentiated packages of care for those who are diagnosed late with low cluster of differentiation 4 (CD4) cell counts, and those at risk of cryptococcal disease, particularly where CrAg screening is unavailable.The authors do not believe that further research is required to show the efficacy of primary antifungal prophylaxis in reducing the occurrence of cryptococcal disease, particularly among patients where CrAg status is unknown. The cost‐benefit of providing antifungal prophylaxis to CrAg‐negative patients remains an area of debate, due to the low occurrence of cryptococcal disease in this group. Further analyses of the cost effectiveness and feasibility of implementing this intervention in different settings are needed, as well as comparisons between the primary prophylaxis strategy and the strategy of CrAg screening plus pre‐emptive antifungal therapy for those who screened positive.
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Cochrane Central Register of Controlled Trials (CENTRAL) {#CD004773-sec3-0031}
========================================================

\#1 MeSH descriptor: \[HIV Infections\] explode all trees

\#2 MeSH descriptor: \[HIV\] explode all trees

\#3 hiv or hiv‐1\* or hiv‐2\* or hiv1 or hiv2 or (hiv near infect\*) or (human immunodeficiency virus) or (human immunedeficiency virus) or (human immune‐deficiency virus) or (human immuno‐deficiency virus) or (human immune deficiency virus) or (human immuno deficiency virus) or (acquired immunodeficiency syndrome) or (acquired immunedeficiency syndrome) or (acquired immuno‐deficiency syndrome) or (acquired immune‐deficiency syndrome) or (acquired immun\* deficiency syndrome):ti,ab,kw (Word variations have been searched)

\#4 MeSH descriptor: \[Lymphoma, AIDS‐Related\] this term only

\#5 MeSH descriptor: \[Sexually Transmitted Diseases, Viral\] this term only

\#6 \#1 or \#2 or \#3 or \#4 or \#5 Publication Year from 1980 to 2017

\#7 prevent\* or prophyl\* or chemoprevent\* or chemoprophyla\*:ti,ab,kw (Word variations have been searched)

\#8 MeSH descriptor: \[Antifungal Agents\] explode all trees

\#9 azole\* or fluconazole or amphotericin or flucytosine or voriconazole or diflucan or itraconazole:ti,ab,kw (Word variations have been searched)

\#10 \#8 or \#9\#6 and 7 and \#10

MEDLINE PubMed {#CD004773-sec3-0032}
==============

SearchQuery[\#17](#17)Search ((((((((\"Cryptococcosis\"\[Mesh\] OR \"Meningitis, Cryptococcal\"\[Mesh\]) AND ( \"1980/01/01\"\[PDat\] : \"3000/12/31\"\[PDat\] ))) OR ((cryptococcosis OR cryptococcoses OR torulosis OR toruloses OR cryptococcal OR cryptococal OR cryptococcus OR toruloma OR torulomas) AND ( \"1980/01/01\"\[PDat\] : \"3000/12/31\"\[PDat\] ))) AND ( \"1980/01/01\"\[PDat\] : \"3000/12/31\"\[PDat\] ))) AND ((prevent\* \[Title/Abstract\] OR prophyl\* \[Title/Abstract\] OR chemoprevent\* \[Title/Abstract\] OR chemoprophyla\* \[Title/Abstract\] or primary \[Title/Abstract\]) AND ( \"1980/01/01\"\[PDat\] : \"3000/12/31\"\[PDat\] ))) AND (((randomized controlled trial \[pt\] OR controlled clinical trial \[pt\] OR randomized \[tiab\] OR placebo \[tiab\] OR drug therapy \[sh\] OR randomly \[tiab\] OR trial \[tiab\] OR groups \[tiab\]) NOT (animals \[mh\] NOT humans \[mh\])) AND ( \"1980/01/01\"\[PDat\] : \"3000/12/31\"\[PDat\] ))) AND ((((HIV Infections\[MeSH\] OR HIV\[MeSH\] OR hiv\[tiab\] OR hiv‐1\*\[tiab\] OR hiv‐2\*\[tiab\] OR hiv1\[tiab\] OR hiv2\[tiab\] OR hiv infect\*\[tiab\] OR human immunodeficiency virus\[tiab\] OR human immunedeficiency virus\[tiab\] OR human immuno‐deficiency virus\[tiab\] OR human immune‐deficiency virus\[tiab\] OR ((human immun\*\[tiab\]) AND (deficiency virus\[tiab\])) OR acquired immunodeficiency syndrome\[tiab\] OR acquired immunedeficiency syndrome\[tiab\] OR acquired immuno‐deficiency syndrome\[tiab\] OR acquired immune‐deficiency syndrome\[tiab\] OR ((acquired immun\*\[tiab\]) AND (deficiency syndrome\[tiab\]))))) AND ( \"1980/01/01\"\[PDat\] : \"3000/12/31\"\[PDat\] )) Sort by: PublicationDate Filters: Publication date from 1980/01/01[\#16](#16)Search (((\"Cryptococcosis\"\[Mesh\] OR \"Meningitis, Cryptococcal\"\[Mesh\]) AND ( \"1980/01/01\"\[PDat\] : \"3000/12/31\"\[PDat\] ))) OR ((cryptococcosis OR cryptococcoses OR torulosis OR toruloses OR cryptococcal OR cryptococal OR cryptococcus OR toruloma OR torulomas) AND ( \"1980/01/01\"\[PDat\] : \"3000/12/31\"\[PDat\] )) Sort by: PublicationDate Filters: Publication date from 1980/01/01

[\#6](#6)Search ((((((randomized controlled trial \[pt\] OR controlled clinical trial \[pt\] OR randomized \[tiab\] OR placebo \[tiab\] OR drug therapy \[sh\] OR randomly \[tiab\] OR trial \[tiab\] OR groups \[tiab\]) NOT (animals \[mh\] NOT humans \[mh\])) AND ( \"1980/01/01\"\[PDat\] : \"3000/12/31\"\[PDat\] ))) AND ((((Antifungal agents\[mh\] OR azole\*\[tiab\] OR fluconazole\[tiab\] OR amphotericin\[tiab\] OR flucytosine\[tiab\] OR voriconazole\[tiab\] OR diflucan\[tiab\] OR itraconazole\[tiab\] OR rifampin\[tiab\] OR 5‐FC\[tiab\]))) AND ( \"1980/01/01\"\[PDat\] : \"3000/12/31\"\[PDat\] ))) AND ((prevent\* \[Title/Abstract\] OR prophyl\* \[Title/Abstract\] OR chemoprevent\* \[Title/Abstract\] OR chemoprophyla\* \[Title/Abstract\]) AND ( \"1980/01/01\"\[PDat\] : \"3000/12/31\"\[PDat\] ))) AND ((((HIV Infections\[MeSH\] OR HIV\[MeSH\] OR hiv\[tiab\] OR hiv‐1\*\[tiab\] OR hiv‐2\*\[tiab\] OR hiv1\[tiab\] OR hiv2\[tiab\] OR hiv infect\*\[tiab\] OR human immunodeficiency virus\[tiab\] OR human immunedeficiency virus\[tiab\] OR human immuno‐deficiency virus\[tiab\] OR human immune‐deficiency virus\[tiab\] OR ((human immun\*\[tiab\]) AND (deficiency virus\[tiab\])) OR acquired immunodeficiency syndrome\[tiab\] OR acquired immunedeficiency syndrome\[tiab\] OR acquired immuno‐deficiency syndrome\[tiab\] OR acquired immune‐deficiency syndrome\[tiab\] OR ((acquired immun\*\[tiab\]) AND (deficiency syndrome\[tiab\]))))) AND ( \"1980/01/01\"\[PDat\] : \"3000/12/31\"\[PDat\] )) Sort by: PublicationDate Filters: Publication date from 1980/01/01[\#5](#5)Search (randomized controlled trial \[pt\] OR controlled clinical trial \[pt\] OR randomized \[tiab\] OR placebo \[tiab\] OR drug therapy \[sh\] OR randomly \[tiab\] OR trial \[tiab\] OR groups \[tiab\]) NOT (animals \[mh\] NOT humans \[mh\]) Sort by: PublicationDate Filters: Publication date from 1980/01/01[\#4](#4)Search ((Antifungal agents\[mh\] OR azole\*\[tiab\] OR fluconazole\[tiab\] OR amphotericin\[tiab\] OR flucytosine\[tiab\] OR voriconazole\[tiab\] OR diflucan\[tiab\] OR itraconazole\[tiab\] OR rifampin\[tiab\] OR 5‐FC\[tiab\])) Sort by: PublicationDate Filters: Publication date from 1980/01/01[\#3](#3)Search prevent\* \[Title/Abstract\] OR prophyl\* \[Title/Abstract\] OR chemoprevent\* \[Title/Abstract\] OR chemoprophyla\* \[Title/Abstract\] Sort by: PublicationDate Filters: Publication date from 1980/01/01[\#2](#2)Search ((HIV Infections\[MeSH\] OR HIV\[MeSH\] OR hiv\[tiab\] OR hiv‐1\*\[tiab\] OR hiv‐2\*\[tiab\] OR hiv1\[tiab\] OR hiv2\[tiab\] OR hiv infect\*\[tiab\] OR human immunodeficiency virus\[tiab\] OR human immunedeficiency virus\[tiab\] OR human immuno‐deficiency virus\[tiab\] OR human immune‐deficiency virus\[tiab\] OR ((human immun\*\[tiab\]) AND (deficiency virus\[tiab\])) OR acquired immunodeficiency syndrome\[tiab\] OR acquired immunedeficiency syndrome\[tiab\] OR acquired immuno‐deficiency syndrome\[tiab\] OR acquired immune‐deficiency syndrome\[tiab\] OR ((acquired immun\*\[tiab\]) AND (deficiency syndrome\[tiab\])))) Sort by: PublicationDate Filters: Publication date from 1980/01/01[\#1](#1)Search ((HIV Infections\[MeSH\] OR HIV\[MeSH\] OR hiv\[tiab\] OR hiv‐1\*\[tiab\] OR hiv‐2\*\[tiab\] OR hiv1\[tiab\] OR hiv2\[tiab\] OR hiv infect\*\[tiab\] OR human immunodeficiency virus\[tiab\] OR human immunedeficiency virus\[tiab\] OR human immuno‐deficiency virus\[tiab\] OR human immune‐deficiency virus\[tiab\] OR ((human immun\*\[tiab\]) AND (deficiency virus\[tiab\])) OR acquired immunodeficiency syndrome\[tiab\] OR acquired immunedeficiency syndrome\[tiab\] OR acquired immuno‐deficiency syndrome\[tiab\] OR acquired immune‐deficiency syndrome\[tiab\] OR ((acquired immun\*\[tiab\]) AND (deficiency syndrome\[tiab\])))) Sort by: PublicationDate

Embase {#CD004773-sec3-0033}
======

1 'human immunodeficiency virus infection\'/exp or 'human immunodeficiency virus infection\'.mp. or 'human immunodeficiency virus\'/exp or 'human immunodeficiency virus\'.mp. or 'human immunodeficiency virus\':ab,ti.mp. or 'human immuno+deficiency virus\':ab,ti.mp. or 'human immunedeficiency virus\':ab,ti.mp. or 'human immune+deficiency virus\':ab,ti.mp. or hiv:ab,ti.mp. or 'hiv‐1\':ab,ti.mp. or 'hiv‐2\':ab,ti.mp. or 'acquired immunodeficiency syndrome\':ab,ti.mp. or 'acquired immuno+deficiency syndrome\':ab,ti.mp. or 'acquired immunedeficiency syndrome\':ab,ti.mp. or 'acquired immune+deficiency syndrome\':ab,ti.mp. \[mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word\] (391379)

2 'randomized controlled trial\'/de or 'randomized controlled trial\'.mp. or random\*:ab,ti.mp. or trial:ti.mp. or allocat\*:ab,ti.mp. or factorial\*:ab,ti.mp. or placebo\*:ab,ti.mp. or assign\*:ab,ti.mp. or volunteer\*:ab,ti.mp. \[mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word\] (614214)

3 'crossover procedure\'/de or 'crossover procedure\'.mp. or 'double‐blind procedure\'/de or 'double‐blind procedure\'.mp. or 'single‐blind procedure\'/de or 'single‐blind procedure\'.mp. \[mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word\] (206231)

4 (crossover or cross‐over).ab. or (crossover or cross‐over).ti. (89952)

5 2 or 3 or 4 (713029)

6 antifungal agent.mp. or exp antifungal agent/ (336774)

7 (fluconazole or amphotericin or flucytosine or voriconazole or diflucan or itraconazole or rifampin or 5‐FC).mp. \[mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word\] (106224)

8 (prevent\* or prophyl\* or chemoprevent\* or chemoprophyla\*:).ab. or (prevent\* or prophyl\* or chemoprevent\* or chemoprophyla\*:).ti. (1772805)

9 prophylaxis/ (100999)

10 6 or 7 (348179)

11 8 or 9 (1793846)

12 1 and 5 and 10 and 11 (152)

CINAHL EBSCOHost {#CD004773-sec3-0034}
================

Search ID\#Search TermsS4S1 AND S2 AND S3S3TI ( prevent\* or prophyl\* or chemoprevent\* or chemoprophyla\* ) OR AB ( prevent\* or prophyl\* or chemoprevent\* or chemoprophyla\* )S2MH antifungal agents OR ( fluconazole or amphotericin or flucytosine or voriconazole or diflucan or itraconazole or rifampin or 5‐FC )S1MH hiv infection OR MH hiv OR TX ( hiv or hiv‐1\* or hiv‐2\* or hiv1 or hiv2 or (hiv near infect\*) or (human immunodeficiency virus) or (human immunedeficiency virus) or (human immune‐deficiency virus) or (human immuno‐deficiency virus) or (human immune deficiency virus) or (human immuno deficiency virus) or (acquired immunodeficiency syndrome) or (acquired immunedeficiency syndrome) or (acquired immuno‐deficiency syndrome) or (acquired immune‐deficiency syndrome) or (acquired immun\* deficiency sy \...

Comparison 1Antifungal versus no antifungal (placebo or standard care)Outcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 All‐cause mortality](#CD004773-fig-00101){ref-type="fig"}Analysis 1.1Comparison 1 Antifungal versus no antifungal (placebo or standard care), Outcome 1 All‐cause mortality.63220Risk Ratio (M‐H, Random, 95% CI)1.07 \[0.80, 1.43\][2 All‐cause mortality by CD4 count](#CD004773-fig-00102){ref-type="fig"}Analysis 1.2Comparison 1 Antifungal versus no antifungal (placebo or standard care), Outcome 2 All‐cause mortality by CD4 count.63190Risk Ratio (M‐H, Random, 95% CI)1.03 \[0.75, 1.42\]2.1 CD4 \< 100190Risk Ratio (M‐H, Random, 95% CI)0.23 \[0.05, 1.02\]2.2 CD4 \< 15021124Risk Ratio (M‐H, Random, 95% CI)1.38 \[0.99, 1.93\]2.3 CD4 \< 20021648Risk Ratio (M‐H, Random, 95% CI)1.04 \[0.81, 1.34\]2.4 CD4 \< 3001328Risk Ratio (M‐H, Random, 95% CI)0.54 \[0.24, 1.20\][3 All‐cause mortality by baseline CrAG status](#CD004773-fig-00103){ref-type="fig"}Analysis 1.3Comparison 1 Antifungal versus no antifungal (placebo or standard care), Outcome 3 All‐cause mortality by baseline CrAG status.63220Risk Ratio (M‐H, Random, 95% CI)1.07 \[0.80, 1.43\]3.1 CrAG‐negative at baseline21609Risk Ratio (M‐H, Random, 95% CI)0.59 \[0.14, 2.43\]3.2 No CrAG screening41611Risk Ratio (M‐H, Random, 95% CI)1.22 \[0.91, 1.63\][4 All‐cause mortality by time‐to‐ART initiation](#CD004773-fig-00104){ref-type="fig"}Analysis 1.4Comparison 1 Antifungal versus no antifungal (placebo or standard care), Outcome 4 All‐cause mortality by time‐to‐ART initiation.63220Risk Ratio (M‐H, Random, 95% CI)1.07 \[0.80, 1.43\]4.1 Triple ART; median 11 weeks to initiation11519Risk Ratio (M‐H, Random, 95% CI)1.03 \[0.79, 1.35\]4.2 No triple ART; \> 11 weeks to initiation51701Risk Ratio (M‐H, Random, 95% CI)1.03 \[0.67, 1.59\][5 All‐cause mortality by ART received](#CD004773-fig-00105){ref-type="fig"}Analysis 1.5Comparison 1 Antifungal versus no antifungal (placebo or standard care), Outcome 5 All‐cause mortality by ART received.63220Risk Ratio (M‐H, Random, 95% CI)1.07 \[0.80, 1.43\]5.1 Single or dual ART51701Risk Ratio (M‐H, Random, 95% CI)1.03 \[0.67, 1.59\]5.2 Triple ART11519Risk Ratio (M‐H, Random, 95% CI)1.03 \[0.79, 1.35\][6 All‐cause mortality by type of antifungal drug](#CD004773-fig-00106){ref-type="fig"}Analysis 1.6Comparison 1 Antifungal versus no antifungal (placebo or standard care), Outcome 6 All‐cause mortality by type of antifungal drug.6Risk Ratio (M‐H, Random, 95% CI)Subtotals only6.1 Flucaonazole32438Risk Ratio (M‐H, Random, 95% CI)0.99 \[0.62, 1.59\]6.2 Itraconazole3782Risk Ratio (M‐H, Random, 95% CI)1.12 \[0.70, 1.80\][7 Cryptococcal disease occurrence](#CD004773-fig-00107){ref-type="fig"}Analysis 1.7Comparison 1 Antifungal versus no antifungal (placebo or standard care), Outcome 7 Cryptococcal disease occurrence.75000Risk Ratio (M‐H, Random, 95% CI)0.29 \[0.17, 0.49\][8 Cryptococcal disease occurrence by CD4 count](#CD004773-fig-00108){ref-type="fig"}Analysis 1.8Comparison 1 Antifungal versus no antifungal (placebo or standard care), Outcome 8 Cryptococcal disease occurrence by CD4 count.75000Risk Ratio (M‐H, Random, 95% CI)0.29 \[0.17, 0.49\]8.1 CD4 \< 10021870Risk Ratio (M‐H, Random, 95% CI)0.40 \[0.21, 0.78\]8.2 CD4 \< 15021124Risk Ratio (M‐H, Random, 95% CI)0.25 \[0.08, 0.76\]8.3 CD4 \< 20021648Risk Ratio (M‐H, Random, 95% CI)0.06 \[0.01, 0.31\]8.4 CD4 \< 3001358Risk Ratio (M‐H, Random, 95% CI)0.2 \[0.01, 4.14\][9 Cryptococcal disease occurrence by ART received](#CD004773-fig-00109){ref-type="fig"}Analysis 1.9Comparison 1 Antifungal versus no antifungal (placebo or standard care), Outcome 9 Cryptococcal disease occurrence by ART received.75000Risk Ratio (M‐H, Random, 95% CI)0.29 \[0.17, 0.49\]9.1 No triple ART51701Risk Ratio (M‐H, Random, 95% CI)0.28 \[0.13, 0.60\]9.2 Triple ART23299Risk Ratio (M‐H, Random, 95% CI)0.18 \[0.03, 1.30\][10 Cryptococcal disease occurrence by type of antifungal drug](#CD004773-fig-00110){ref-type="fig"}Analysis 1.10Comparison 1 Antifungal versus no antifungal (placebo or standard care), Outcome 10 Cryptococcal disease occurrence by type of antifungal drug.75000Risk Ratio (M‐H, Random, 95% CI)0.29 \[0.17, 0.49\]10.1 Fluconazole44218Risk Ratio (M‐H, Random, 95% CI)0.32 \[0.16, 0.62\]10.2 Itraconazole3782Risk Ratio (M‐H, Random, 95% CI)0.12 \[0.03, 0.51\][11 Cryptococcal disease occurrence by time‐to‐ART initiation](#CD004773-fig-00111){ref-type="fig"}Analysis 1.11Comparison 1 Antifungal versus no antifungal (placebo or standard care), Outcome 11 Cryptococcal disease occurrence by time‐to‐ART initiation.75000Risk Ratio (M‐H, Random, 95% CI)0.29 \[0.17, 0.49\]11.1 ART commenced; median 5 days after screening11780Risk Ratio (M‐H, Random, 95% CI)0.39 \[0.18, 0.84\]11.2 ART commenced; median 11 weeks after diagnosis11519Risk Ratio (M‐H, Random, 95% CI)0.06 \[0.01, 0.41\]11.3 ART commenced; median \> 11 weeks after diagnosis51701Risk Ratio (M‐H, Random, 95% CI)0.28 \[0.13, 0.60\][12 Cryptococcal disease occurrence by baseline CrAg status](#CD004773-fig-00112){ref-type="fig"}Analysis 1.12Comparison 1 Antifungal versus no antifungal (placebo or standard care), Outcome 12 Cryptococcal disease occurrence by baseline CrAg status.7Risk Ratio (M‐H, Random, 95% CI)Subtotals only12.1 CrAG‐negative at baseline33257Risk Ratio (M‐H, Random, 95% CI)0.23 \[0.06, 0.90\]12.2 CrAG‐positive at baseline1133Risk Ratio (M‐H, Random, 95% CI)0.39 \[0.15, 1.01\]12.3 No CrAG screening41611Risk Ratio (M‐H, Random, 95% CI)0.21 \[0.08, 0.56\][13 Cryptococcal‐specific mortality](#CD004773-fig-00113){ref-type="fig"}Analysis 1.13Comparison 1 Antifungal versus no antifungal (placebo or standard care), Outcome 13 Cryptococcal‐specific mortality.53813Risk Ratio (M‐H, Random, 95% CI)0.29 \[0.11, 0.72\][14 Clinical resistance of *Candida* to antifungal](#CD004773-fig-00114){ref-type="fig"}Analysis 1.14Comparison 1 Antifungal versus no antifungal (placebo or standard care), Outcome 14 Clinical resistance of *Candida* to antifungal.4Risk Ratio (M‐H, Random, 95% CI)Subtotals only14.1 Fluconazole31198Risk Ratio (M‐H, Random, 95% CI)0.93 \[0.56, 1.56\]14.2 Itraconazole1129Risk Ratio (M‐H, Random, 95% CI)3.14 \[0.13, 75.69\][15 Microbiological resistance of *Candida* to fluconazole](#CD004773-fig-00115){ref-type="fig"}Analysis 1.15Comparison 1 Antifungal versus no antifungal (placebo or standard care), Outcome 15 Microbiological resistance of *Candida* to fluconazole.4Risk Ratio (M‐H, Random, 95% CI)Subtotals only15.1 Surveillance sampling, fluconazole used, all *Candida* species3539Risk Ratio (M‐H, Random, 95% CI)1.25 \[1.00, 1.55\]15.2 Sampling from clinical disease, itraconazole used, *C. albicans* only195Risk Ratio (M‐H, Random, 95% CI)6.19 \[1.41, 27.10\][16 Treatment discontinuation](#CD004773-fig-00116){ref-type="fig"}Analysis 1.16Comparison 1 Antifungal versus no antifungal (placebo or standard care), Outcome 16 Treatment discontinuation.42317Risk Ratio (M‐H, Random, 95% CI)1.01 \[0.91, 1.13\][17 Any serious adverse event](#CD004773-fig-00117){ref-type="fig"}Analysis 1.17Comparison 1 Antifungal versus no antifungal (placebo or standard care), Outcome 17 Any serious adverse event.4888Risk Ratio (M‐H, Random, 95% CI)1.08 \[0.83, 1.41\][18 Any adverse events](#CD004773-fig-00118){ref-type="fig"}Analysis 1.18Comparison 1 Antifungal versus no antifungal (placebo or standard care), Outcome 18 Any adverse events.42317Risk Ratio (M‐H, Random, 95% CI)1.07 \[0.88, 1.30\][19 Common adverse events](#CD004773-fig-00119){ref-type="fig"}Analysis 1.19Comparison 1 Antifungal versus no antifungal (placebo or standard care), Outcome 19 Common adverse events.4Risk Ratio (M‐H, Random, 95% CI)Subtotals only19.1 Diarrhoea2424Risk Ratio (M‐H, Random, 95% CI)1.31 \[0.32, 5.29\]19.2 Abdominal pain21814Risk Ratio (M‐H, Random, 95% CI)0.91 \[0.56, 1.46\]19.3 Nausea21814Risk Ratio (M‐H, Random, 95% CI)0.97 \[0.64, 1.47\]19.4 Rash42317Risk Ratio (M‐H, Random, 95% CI)1.03 \[0.56, 1.91\]

**DateEventDescription**28 August 2018New search has been performedThis is an update of a review last published in 2005 ([@CD004773-bbs2-0061]). The review author team updated the protocol extensively, and differences are highlighted in the '[Differences between protocol and review](Differences between protocol and review)\' section.28 August 2018New citation required and conclusions have changedNine trials (5426 participants) met the inclusion criteria of this review update.One study included in the [@CD004773-bbs2-0061] review did not meet our inclusion criteria. We also included two studies published after the [@CD004773-bbs2-0061] review ([@CD004773-bbs2-0004]; [@CD004773-bbs2-0006]).\
We considered outcomes related to resistance in trials looking at prevention of *Candida* infection, which were not included in the [@CD004773-bbs2-0061] review.\
The findings of this review update are consistent with those of previous published reviews, which both showed that antifungal prophylaxis may have made little or no difference to all‐cause mortality, but reduced the occurrence of cryptococcal disease ([@CD004773-bbs2-0061]; [@CD004773-bbs2-0054]). However, the findings from this review are more relevant to current HIV populations.

This is an update of a previous Cochrane review ([@CD004773-bbs2-0061]). The new review author team extensively revised the protocol, which is available on the CIDG website at [cidg.cochrane.org/our‐reviews](cidg.cochrane.org/our‐reviews) under the subheading 'Related content\'.

Several outcomes that were not originally included in the protocol were added during the review process. This included mortality due to cryptococcal disease and microbiological resistance in *Candida* species. We included these outcomes to clarify the benefits and harms of the intervention.

Adherence was reported as described in the trial.

Several outcomes measures changed from rate to proportion. There was no intention of analysing these outcomes as rates and the teams intention was always to look at proportions, however incorrect wording was used in the published protocol and this was corrected in the final review.

We counted cases of cryptococcal disease in the studies if the investigators referred to them as confirmed cases. We did not count cases that the authors referred to as suspected. We also didn\'t rely on the study authors specifically describing the method of diagnosis.

We included studies that didn\'t specify the method of cryptococcal diagnosis.

We included studies that gave co‐trimoxazole prophylaxis in both groups, as we decided that in order for the review to be relevant in today\'s setting, we would need to include studies where standard HIV co‐interventions, such as co‐trimoxazole and isoniazid prophylaxis were provided.

We included studies that provided other co‐interventions with antifungal prophylaxis. We felt this was necessary in order to include the most recent and applicable evidence. We minimized the confounding effect of the co‐interventions as described previously.

*Candida* resistance to fluconazole was assessed by microbiological assessment and not restricted to clinical diseases. We used an MIC \> 16 µg/mL to define resistance to fluconazole, according to the majority of the study definitions.

We amended the comparator to placebo or no antifungal intervention in response to peer review comments.

We amended our subgroup analyses in response to peer review comments to include the following subgroups for all‐cause mortality and cryptococcal disease occurrence.

CD4+ threshold for initiation of prophylaxisCrAg status at baselineTiming of ART initiationType of ARTType of antifungal drug

Characteristics of included studies \[ordered by study ID\] {#CD004773-sec2-0018}
===========================================================

[@CD004773-bbs2-0001]Methods**Study design**: randomized controlled trial (RCT)Participants**Inclusion criteria**: 18 to 60 years, documented HIV infection, Karnofsky score of \> 70 (normal activity possible with effort), absolute CD4 lymphocyte count of \< 200 cells/µL, and residence in the Chiang Mai area.\
**Exclusion criteria**: history of systemic fungal infections, use of systemic antifungal therapy within 2 weeks before study entry, history of active tuberculosis, pregnancy or breastfeeding, a history of intolerance to triazole compounds, failure to use a medically approved and effective method of birth control, inability to take oral medications, use of a medication with a known interaction with itraconazole, and serum aminotransferase levels at \> 5 times the upper limit of normal.\
**Number randomized**: 129\
**Descriptive baseline data:**\
Age \[mean (range) years\]: itraconazole 33.4 (22 to 51); placebo 33.3 (23 to 58)Sex \[% male\]: itraconazole 38%; placebo 38%CD4 count \[median cells/μL\]: itraconazole (60); placebo (73)ART regimen provided: non‐tripleTime to ART: not reportedCrAg status: not reported% on ART: 6.2%Duration of follow‐up \[median (range) weeks\]: itraconazole \[40 (6 to 104)\]; placebo \[35 (5 to 104)\
**Dropouts during study period:** 0InterventionsItraconazole 200 mg dailyPlaceboOutcomes**All‐cause mortality** at 104 weeks**Cryptococcal disease incidence** over 104 weeks**Adherence**: reported as a percentage above a defined threshold ‐ by calculating the proportion of doses reportedly missed at each visit and using that value to estimate the number of days each week that study drugs were taken.**Treatment discontinuation** over 104 weeks**Adverse events** over 104 weeksNotes**Country**: Thailand\
**Setting**: hospital\
**Dates**: March 1998 to February 2000 (recruitment)\
**Funding**: Funded by Janssen Pharmaceuticals\
**Others**: Study was stopped in March 2000 after the first patient completed 104 weeks of follow‐up, when an interim analysis showed significant difference in the occurrence of systemic fungal infections between the two groups.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskThe patients were randomly assigned to receive itraconazole or placebo in a 1:1 ratio. Randomization was performed by the drug manufacturer (Janssen Pharmaceutical) with a computerized randomization list based on a block size of 6.Allocation concealment (selection bias)Low riskThe medication was packaged in sequentially numbered boxes that were dispensed to successive patients.Blinding of participants and personnel (performance bias) All outcomesLow risk\"A prospective, randomized, placebo‐controlled, double‐blind study was conducted to compare the safety and efficacy of itraconazole (200 mg per day) with that of placebo.\"\
Placebo was identical in appearance to the study drugBlinding of outcome assessment (detection bias) All outcomesLow riskStudy was described as double‐blind. The authors did not explicitly state that the outcome assessors were blinded. However, the outcomes we assessed in this review were mostly objective.Incomplete outcome data (attrition bias) All outcomesLow riskNo participants lost to follow‐up.Selective reporting (reporting bias)Low riskNo protocol available, however, no suggestion of selective reporting seen.Other biasUnclear riskGrant received from Janssen Pharmaceuticals; Janssen also randomized participants. No information on specific conflicts of interests provided.[@CD004773-bbs2-0002]Methods**Study design**: RCTParticipants**Inclusion criteria**: adult patients (\> 14 years old) with documented HIV infection and CD4 counts \< 100 cells/µL\
**Exclusion criteria**: systemic fungal infection, allergy or intolerance to fluconazole, liver enzymes \> 5 times the normal limit, positive serum cryptococcal antigen, and pregnancy and lactation in women\
**Number randomized**: 90\
**Descriptive baseline data:**\
Age \[mean (range) years\]: fluconazole 33.0 (25 to 46); placebo 32.2 (20 to 53)Sex \[% male\]: fluconazole 70%; placebo 61%CD4 count \[median cells/μL\]: fluconazole (17.2); placebo (23.7)CD4 count \[mean (range) cells/μL\]: fluconazole 29.1 (1.3 to 97.8); placebo 31.2 (1.4 to 96)ART regimen provided: non‐tripleTime to ART: not reportedCrAg status: CrAG‐negative: 90/90% on ART: 6.7%Duration of follow‐up \[median (range) weeks\]: fluconazole \[152 (1 to 554)\]; placebo \[136 (1 to 540)\]\
**Dropouts during study period:** not reportedInterventionsFluconazole 400 mg weeklyPlaceboOutcomes**All‐cause mortality** over 152.5 and 136.5 days in the fluconazole and placebo groups respectively**Cryptococcal disease occurrence** over 152.5 and 136.5 days in the fluconazole and placebo groups respectively**Cryptococcal specific mortality** over 152.5 and 136.5 days in the fluconazole and placebo groups respectively**Severe adverse events** over 152.5 and 136.5 days in the fluconazole and placebo groups respectivelyNotes**Location**: Thailand\
**Setting**: hospital\
**Dates**: February 2000 to August 2001 (recruitment)\
**Funding**: not reported\
**Others**: study was terminated because of the national policy that fluconazole should be used in practice.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskNo method recordedAllocation concealment (selection bias)Unclear riskNo method recordedBlinding of participants and personnel (performance bias) All outcomesLow risk\"Double‐blind\" patients received placebo or study medicationBlinding of outcome assessment (detection bias) All outcomesLow riskStudy was described as double‐blind. The authors did not explicitly state that the outcome assessors were blinded. However, the outcomes we assessed in this review were mostly objective.Incomplete outcome data (attrition bias) All outcomesUnclear riskLoss to follow‐up and dropout rates not recordedSelective reporting (reporting bias)Unclear riskLoss to follow‐up, dropout rates, and adverse events not reported in detail (\"No serious adverse reaction related to medication was seen during the study\")Other biasUnclear riskNo information provided on conflicts of interest[@CD004773-bbs2-0003]Methods**Study design**: open label RCTParticipants**Inclusion criteria**: documentation of HIV infection, a CD4+ T cell count of less than or equal to 150 cells/mm³ within 30 days before study entry, age over 13, weight \> 40 kg, experienced one episode of oesophageal candidiasis in 6 months before randomization.\
**Exclusion criteria**: Pregnant, prior resistant *Candida* infection, azole allergy or intolerance, development of 3 episodes of OPC within 12 weeks before study entry, history of EC, need for systemic antifungal therapy, receipt of 11 months of continuous systemic or oral topical antifungal therapy within the past 3 months, severe liver disease, treated for oppurtunistic infection 14 days prior to randomization, subjects receiving medications contraindicated with fluconazole.\
**Number randomized**: 829\
**Descriptive baseline data:**\
Age \[median (range) years\]: fluconazole‐continuous therapy 38 (21 to 71); fluconazole‐episodic 38 (19 to 67); combined 38 (19 to 71)Sex \[% male\]: fluconazole‐continuous therapy 81%; fluconazole‐episodic 83%; combined 82%CD4 count \[median (range) cells/μL\]: fluconazole‐continuous therapy 52 (0 to 250); fluconazole‐episodic 50 (0 to 209); combined 50 (0 to 250)ART regimen provided: non‐tripleTime to ART: not reportedCrAg status: not reported% on ART: 82%Duration of follow‐up \[median (range) months\]: 24 (\< 1 to 44)\
**Dropouts during study period:** fluconazole‐continuous therapy 13%; fluconazole‐episodic 8.9%; combined 11%InterventionsFluconazole 200 mg three times per weekEpisode driven fluconazole treatment for *Candida* infectionsOutcomes**All‐cause mortality** over a median duration of 24 months follow‐up**Cryptococcal disease incidence** over a median duration of 24 months follow‐up**Adverse events** over a median duration of 24 months follow‐upNotes**Location**: multi‐centre ‐ USA\
**Setting**: hospitals\
**Dates**: May 1997 to April 2000 (recruitment)\
**Funding**: Trial was funded by the National Institute of Allergy and Infectious Diseases, National Institutes of Health and Pfizer.\
**Others:** Defnition of clinically resistant *Candida* infection:\
\"A subject was considered to have an fluconazole resistant infection if (1) signs or symptoms of oesophageal candidiasis (EC) worsened after 7 days of therapy and either endoscopically confirmed EC or worsening oropharyngeal candidiasis (OPC) occurred, accompanied by oesophageal symptoms; (2) OPC remained after 14 days of therapy for EC; or (3) OPC or confirmed EC was present after 21 days of therapy\"***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskSequence generation not described.\
"Eligible subjects were randomised at a ratio of 1:1 to undergo 1 of 2 different management strategies"Allocation concealment (selection bias)Unclear riskAllocation concealment not describedBlinding of participants and personnel (performance bias) All outcomesLow riskOpen label, outcomes measured not prone to performance bias.Blinding of outcome assessment (detection bias) All outcomesUnclear riskOpen label trial so blinding of clinical assessors not possible. No blinding of laboratory staff assessed.Incomplete outcome data (attrition bias) All outcomesLow riskReasons for treatment discontinuation or attrition addressed in comprehensive flow diagram\
184/416 in episodic arm prematurely discontinued randomized strategy\
205/413 in continuous arm prematurely discontinued randomized strategy\
Attrition balanced between arms -- majority exited due to non‐compliance (balanced between arms)Selective reporting (reporting bias)Low riskProtocol available. All expected outcomes reported.Other biasLow riskFunding information reported and conflicts of interests addressed[@CD004773-bbs2-0004]Methods**Study design**: open label RCTParticipants**Inclusion criteria**: HIV‐positive adults and children who were 5 years of age or older, who had not received previous ART, and who had a CD4+ count of fewer than 100 cells per cubic millimetre.\
**Exclusion criteria**: pregnancy or breast‐feeding, had received single‐dose nevirapine to prevent mother to‐child transmission of HIV, or had any contraindications to the trial drugs.\
**Number randomized:** 1805\
**Descriptive baseline data:**\
Age \[median (range) years\]: Standard prophylaxis 36 (5 to 78); Enhanced prophylaxis 36 (6 to 71); All patients 36 (5‐78)Sex \[% male\]: Standard prophylaxis 53.8%; Enhanced prophylaxis 52.6%; All patients 53.2%CD4 count \[median (IQR) cells/mm³\]: Standard prophylaxis 36 (16 to 60); Enhanced prophylaxis 38 (16 to 64); All patients 37 (16 to 63)ART regimen provided: tripleTime to ART: 5 days (median)CrAg status: CrAG‐positive: 133/1781% on ART: Standard prophylaxis (82%); Enhanced prophylaxis (87%)Duration of follow‐up (weeks): 48\
**Dropouts during study period:** 3.1%: Standard prophylaxis (24); Enhanced prophylaxis (18)InterventionsEnhanced prophylaxis, which consisted of a single dose (400 mg) of albendazole, 5 days of azithromycin (500 mg once daily), 12 weeks of fluconazole (100 mg once daily), and 12 weeks of a fixed‐dose combination of trimethoprim--sulfamethoxazole (160 mg of trimethoprim and 800 mg of sulfamethoxazole), isoniazid (300 mg), and pyridoxine (25 mg) as a scored once‐daily tablet (total, three tablets per day for 1 to 5 days, then two pills per day for 12 weeks). Doses were halved for children younger than 13 years of age, except for albendazole.Standard prophylaxis which consisted of trimethoprim--sulfamethoxazole alone.Outcomes**Cryptococcal disease occurrence** over 48 weeks**Cryptococcal specific mortality** at 48 weeksNotes**Location**: multicentre; Uganda, Zimbabwe, Malawi, and Kenya\
**Setting**: Urban and peri‐urban centres\
**Dates**: June 2013 to April 2015 (recruitment)\
**Funding**: supported by the Joint Global Health Trials Scheme of the Medical Research Council (MRC), the U.K. Department for International Development, the Wellcome Trust, and the PENTA Foundation.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low risk"computer generated sequential randomisation list with variably sized permuted blocks was prepared by the trial statistician and incorporated securely into the online trial database."Allocation concealment (selection bias)Low risk"The list was concealed until eligibility was confirmed by staff members at the local centre, who then performed the randomisation"Blinding of participants and personnel (performance bias) All outcomesLow risk"open label"; " all nurses and physicians were aware of the trial‐group assignments"\
Although study was unblinded, this was unlikely to have an impact on the outcome we extracted from this study -- cryptococcal diseaseBlinding of outcome assessment (detection bias) All outcomesLow riskOutcome assessment was not blinded -- however, diagnosis of cryptococcal meningitis is not very subjective and we did not think this would have introduced bias, in addition, secondary outcomes were evaluated by a review board.\
"An end‐point review committee whose members were unaware of trial‐group assignment and trial drugs received used protocol defined criteria and grading tables to adjudicate all the secondary clinical outcomes that were reported by the trial physicians"Incomplete outcome data (attrition bias) All outcomesLow risk3% were lost to follow up or withdrew consent after randomizationSelective reporting (reporting bias)Low riskThese were not the results of the full study -- patients were also randomized to receive raltegravir and additional nutrition. However all results relevant to the antifungal prophylaxis portion of the study were reported. The protocol was available for review.Other biasLow riskOf note, patients also were randomized to receive raltegravir or nutritional supplements, which may have impacted some of the outcomes, but unlikely to impact diagnosis of cryptococcal meningitis.[@CD004773-bbs2-0005]Methods**Study design**: RCTParticipants**Inclusion criteria**: age \> 13 years, HIV (western blot or enzyme immunoassay), life expectancy \> 1 year, no life‐threatening infection or malignancy other than Kaposi sarcoma, CD4 \< 150, and residence in a city with high prevalence of histoplasmosis.\
**Exclusion criteria**: Use of investigational drug in last 1 month, pregnancy or lactation, failure to use contraception, history of intolerance, unable to take medications orally, active fungal infection, and use of medication with interaction\
**Number randomized**: 295\
**Descriptive baseline data:**\
Age \[median years\]: itraconazole 37; placebo 36; total 37Sex \[% male\]: itraconazole 96%; placebo 96%; total 96%CD4 count \[median cells/mm³\]: itraconazole 57; placebo 63; total 61ART regimen provided: non‐tripleTime to ART: not reportedCrAg status: not reported% on ART: itraconazole 65%; placebo 63%; total 64%Duration of follow‐up \[mean (range) months\]: 16 (1 to 34)\
**Dropouts during study period:** not reportedInterventionsItraconazole 200 mg dailyPlaceboOutcomes**All‐cause mortality** at 16 months**Cryptococcal disease incidence** over 16 months**Cryptococcal specific mortality** at 16 months***Candida*****species antifungal drug resistance** over 16 months**Treatment discontinuation** over 16 months**Adverse events** over 16 monthsNotes**Location**: USA\
**Setting**: multi‐centre: urban (Kansas, Indianapolis, Nashville, Memphis)\
**Dates**: June 1993 to April 1995 (recruitment)\
**Funding**: The study was supported by the National Institute of Allergy and Infectious Diseases and the Janssen Research Foundation.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskMethod of randomization not explicitly stated, although it is stated that each site had an independent randomization code.\
\"Randomisation was stratified by site, and each site in the study had an independent randomisation code.\"Allocation concealment (selection bias)Unclear riskMethod not reportedBlinding of participants and personnel (performance bias) All outcomesLow riskStudy was described as double‐blind and they received a placebo capsule, which was identical in appearance to itraconazoleBlinding of outcome assessment (detection bias) All outcomesLow riskStudy was described as double‐blind. The authors did not explicitly state that the outcome assessors were blinded. However, the outcomes we assessed in this review were mostly objective.Incomplete outcome data (attrition bias) All outcomesUnclear riskLoss to follow‐up was not reported.Selective reporting (reporting bias)Low riskAll outcomes mentioned in the methods section were reported. No protocol available.Other biasUnclear riskFunded by the National Institute of Allergy and Infectious Diseases and by Janssen Research Foundation. No information provided on role of funding on study design or outcomes assessed.[@CD004773-bbs2-0006]Methods**Study design**: RCTParticipants**Inclusion criteria**: ART‐naïve adults (\> 15 years) with laboratory confirmation of HIV infection (Murex HIV‐1.2.0, Murex Biotech; HIV Uni‐form II plus O, Biomerieux; Cambridge Biotech HIV‐1 Western blot) and a CD4 count less than 200 cells/µL (FACSCount Becton Dickinson, USA)\
**Exclusion criteria**: serum cryptococcal antigen (CrAg; Remel, Lexana, USA) titre \> 1:8 on 2 occasions, pregnancy or lactation, liver transaminases (LFT) \> 3 x upper limit of normal (ULN), and moribund patients.\
**Number randomized**: 1519\
**Descriptive baseline data:**\
Age \[mean (SD) years\]: fluconazole 35.9 (9.1); placebo 35.8 (8.8)Sex \[% male\]: fluconazole 38%; placebo 33%CD4 count \[median (IQR) cells/mm³\]: fluconazole 110 (45 to 160); placebo 112 (48 to 157)ART regimen provided: tripleTime to ART: 11 weeks (median; IQR 7 to 17 weeks); fluconazole 82 days; placebo 87 daysCrAg status: CrAG‐positive:1519/1519% on ART: fluconazole 84%; placebo 87%Duration of follow‐up \[median (range) weeks\]: fluconazole 59 (27 to 124); placebo 60 (28 to 123)\
**Dropouts during study period:** fluconazole (4%); placebo (2.5%)InterventionsFluconazole 200 mg 3 times per weekPlaceboOutcomes**All‐cause mortality** at 60 weeks on placebo and 59 weeks on fluconazole**Cryptococcal disease occurrence** over 60 weeks on placebo and 59 weeks on fluconazole**Cryptococcal specific mortality** at 60 weeks on placebo and 59 weeks on fluconazole**Treatment discontinuation** over 60 weeks on placebo and 59 weeks on fluconazole**Adverse events** over 60 weeks on placebo and 59 weeks on fluconazoleNotes**Location**: Uganda\
**Setting**: multi‐centre ‐ hospitals and clinics\
**Dates**: Sept 2004 to Feb 2008 (recruitment)\
**Funding**: The trial was funded by the Medical Research Council, UK, and the Rockefeller Foundation.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low risk"An independent statistician prepared a list for 1:1 randomisation to fluconazole or matching placebo in random permuted blocks of size 40."Allocation concealment (selection bias)Low risk"Trial drug was packaged and labelled by an independent clinician and pharmacist. Participants were allocated to sequential trial numbers on enrolment and received the corresponding sealed trial drug pack."Blinding of participants and personnel (performance bias) All outcomesLow riskPatients received matching placebo or study medicationBlinding of outcome assessment (detection bias) All outcomesLow risk"The (EPRC) had access to participants' files, hospital notes, verbal autopsy data, and retrospective CrAg results, but were blind to treatment group."Incomplete outcome data (attrition bias) All outcomesLow risk3.3% of participants were lost to follow‐up and 1% withdrew consent.Selective reporting (reporting bias)Low riskTrial was registered on controlled‐trials.comOther biasLow risk"This research was supported by the Medical Research Council, UK, and the Rockefeller Foundation. Neither had a role in design, analysis, or writing of this paper."[@CD004773-bbs2-0007]Methods**Study design**: open label RCTParticipants**Inclusion criteria**: HIV‐positive patients, CD4 \< 350, evidence of active oropharyngeal candidiasis by potassium hydroxide (KOH) preparation and culture and currently not taking any azole compound.\
**Exclusion criteria**: known hypersensitivity to azole compounds, were unable to take oral medications, pregnancy, serum alanine aminotransferase/aspartate aminotransferase ratio more than 10 times normal, serum alkaline phosphatase level more than 5 times normal, bilirubin level was more than 3 times normal.\
**Number randomized**: 62\
**Descriptive baseline data:**\
Age: not reportedSex \[% male\]: not reportedCD4 count \[median (range) cells/mm³\]: fluconazole‐continuous 43 (4 to 116); fluconazole‐intermittent 23 (4 to 191)ART regimen provided: not reportedTime to ART: not reportedCrAg status: not reported% on ART: not reportedDuration of follow‐up \[median (range) months\]: fluconazole‐continuous 9.3 (3 to 20.5); fluconazole‐intermittent 8.4 (3 to 21.5)\
**Dropouts during study period:** fluconazole‐continuous (5%); fluconazole‐intermittent (9.5%)InterventionsContinuous fluconazole 200 mg dailyEpisode driven fluconazole treatment for candidal infectionsOutcomes**Candidal resistance** over 11 monthsNotes**Location**: USA\
**Setting**: tertiary health centre\
**Dates**: not reported\
**Funding**: the trial was funded by the National Institute of Dental Research, the National Institute of Health for the Frederic C. Bartter General Clinical Research Center and Pfizer Inc.\
**Others:** resistance was defined as a rise in MIC \> 16 µg/mL from initial culture, the emergence of new, resistant (MIC \> 16 µg/mL) species any time after the initial culture, or an increase in the proportion of resistant isolates from 10% to at least 50% in a species. Patients who had resistant isolates at the initial culture could be considered to have developed resistance if either of the latter two criteria were present. Microbiological resistance was defined as simply the presence of resistant isolates (MIC \> 16 µg/mL).***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskRandomization was by permuted blocks with a block size of sixAllocation concealment (selection bias)Unclear riskAllocation concealment not discussedBlinding of participants and personnel (performance bias) All outcomesLow riskOpen label trial -- assessment of *Candida* resistance may be prone to performance bias.Blinding of outcome assessment (detection bias) All outcomesUnclear riskBlinding of lab staff not discussed, assessment of *Candida* resistance may be subjective.Incomplete outcome data (attrition bias) All outcomesHigh riskLoss to follow up \< 20% (8%) Those who died at \< 3 months were excluded from analysis.\
4 in intervention group and 16 in control group were excluded based on death \< 3 months.Selective reporting (reporting bias)Low riskNo protocol available; all expected outcomes reported.Other biasHigh riskBaseline characteristics not described. No description of baseline ART status.[@CD004773-bbs2-0008]Methods**Study design**: RCTParticipants**Inclusion criteria**: age \>13 years, HIV (western blot or enzyme immunoassay), CD4 \< 300\
**Exclusion criteria**: history of *Candida* oesophagitis, receiving systemic antifungals, known intolerance of azoles, current pregnancy or lactating\
**Number randomized:** 323\
**Descriptive baseline data:**\
Age (mean): fluconazole (37); placebo (37)Sex \[% male\]: not reportedCD4 count \[median cells/mm³\]: fluconazole (172); placebo (186)ART regimen provided: non‐tripleTime to ART: not reportedCrAg status: not reported% on ART: fluconazole (85%); placebo (75%)Duration of follow‐up \[median (months)\]: 29\
**Dropouts during study period:** fluconazole (5%); placebo (10%)InterventionsFluconazole 200 mg weeklyPlaceboOutcomes**Fluconazole resistance** over 29 monthsNotes**Location**: USA\
**Setting**: multicentre: urban, 14 sites participating in the community programmes for clinical research\
**Dates:** May 1992 to January 1994\
**Funding**: The trial was supported by the National Institute of Allergies and Infectious Diseases (NIAD)\
**Others:** Open label fluconazole was permitted for candidiasis prophylaxis was permitted after two oropharyngeal episodes or one episode of vaginal or oesophageal***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low risk\"patients were randomly assigned to received weekly fluconazole or placebo using a permuted block scheme with randomly mixed block sizes of two and four\"Allocation concealment (selection bias)Unclear riskAllocation concealment not discussedBlinding of participants and personnel (performance bias) All outcomesLow riskDescribed as \"double blind\", and no subjective outcomes assessedBlinding of outcome assessment (detection bias) All outcomesUnclear riskBlinding of laboratory assessors analysing *Candida* isolates not described, assessment of *Candida* resistance may be subjectiveIncomplete outcome data (attrition bias) All outcomesLow risk\"95% of surviving patients receiving fluconazole and 90% of patients receiving placebo attended follow‐up 6 months after finishing the trialSelective reporting (reporting bias)Low riskAll outcomes mentioned in the methods section were reported. No protocol available.Other biasLow risk\"Staff members from NIAID (funding body) were part of the protocol team but had no role in decision to publish the study[@CD004773-bbs2-0009]Methods**Study design**: RCTParticipants**Inclusion criteria**: documented HIV‐1 infection and average of two CD4 counts of \< 300 cells/mL within the past 4 months\
**Exclusion criteria**: women who were pregnant or not using reliable contraception, severe hepatic impairment, known hypersensitivity to azole compounds, a history of previous systemic fungal infection (including oesophageal candidosis) or any fungal infection unresponsive to azole therapy and use of systemic antifungal agents, rifabutin, rifampicin, phenytoin, terfenadine, astemizole, anticholinergic agents, or H2 antagonists.\
**Number randomized**: 374 participants\
**Descriptive baseline data:**\
Age \[mean (SD)\]: itraconazole 37.8 (8.55); placebo 37.6 (8.38)Sex \[% male\]: itraconazole 95.2%; placebo 92%CD4 count \[mean (SD) cells/mm³\]: itraconazole 200 (310); placebo 200 (190)ART regimen provided: non‐tripleTime to ART: not reportedCrAg status: not reported% on ART: itraconazole (79%); placebo (73%)Duration of follow‐up (weeks): 104\
**Dropouts during study period:** itraconazole (9%); placebo (6%)InterventionsItraconazole 200 mg dailyPlaceboOutcomes**All‐cause mortality** at 2 years**Cryptococcal disease incidence** over 2 years**Treatment discontinuation** over 2 years**Adverse events** over 2 yearsNotes**Location**: multicentre; Australia, Canada, South Africa, UK\
**Setting**: clinic\
**Dates:** January 1994 to October 1997\
**Funding**: The trial was funded by the Janssen Research Foundation.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskRandomization was performed by a computer generated codeAllocation concealment (selection bias)Unclear riskNo description of methods of allocation concealment documentedBlinding of participants and personnel (performance bias) All outcomesLow riskDescribed as double blind. Patients received matching placebo or study medication.Blinding of outcome assessment (detection bias) All outcomesLow riskStudy was described as double‐blind. The authors did not explicitly state that the outcome assessors were blinded. However, the outcomes we assessed in this review were mostly objective.Incomplete outcome data (attrition bias) All outcomesLow riskLess than 10% loss to follow‐up over 2 years.Selective reporting (reporting bias)Low riskAll expected outcomes reported, no protocol availableOther biasUnclear riskRole of Janssen research foundation in design of study and any analysis unclear[^7]

Characteristics of excluded studies \[ordered by study ID\] {#CD004773-sec2-0019}
===========================================================

StudyReason for exclusion[@CD004773-bbs2-0010]This was an editorial report of another study.[@CD004773-bbs2-0011]This was a systematic review.[@CD004773-bbs2-0012]This was a retrospective study.[@CD004773-bbs2-0013]This was a retrospective cohort study.[@CD004773-bbs2-0014]The patients included in this study were on secondary prophylaxis for cryptococcal infection.[@CD004773-bbs2-0015]This was a cross‐over study.[@CD004773-bbs2-0016]The comparator in this study was not placebo or no intervention.[@CD004773-bbs2-0017]This study did not report on any of the outcomes we were interested in for this review.[@CD004773-bbs2-0018]This was a retrospective study.[@CD004773-bbs2-0019]This was a retrospective cohort study.[@CD004773-bbs2-0020]This was a retrospective cohort study.[@CD004773-bbs2-0021]The intervention evaluated in this study was community support combined with serum cryptococcal antigen screening.[@CD004773-bbs2-0022]This was a cost‐effectiveness study.[@CD004773-bbs2-0023]This was an editorial report of another study.[@CD004773-bbs2-0024]This was an editorial report.[@CD004773-bbs2-0025]The comparator was not placebo or no intervention.[@CD004773-bbs2-0026]The participants in this study were not randomized.[@CD004773-bbs2-0027]This study did not report on any of the outcomes we were interested in.[@CD004773-bbs2-0028]This was a narrative review.[@CD004773-bbs2-0029]This was a systematic review.[@CD004773-bbs2-0030]This study did not report on any of the outcomes we were interested in for this review.[@CD004773-bbs2-0031]This was a narrative review.

Characteristics of studies awaiting assessment \[ordered by study ID\] {#CD004773-sec2-0020}
======================================================================

[@CD004773-bbs2-0032]MethodsNot knownParticipantsHIV‐positive womenInterventionsNot knownOutcomesNot knownNotesAbstract and full‐text unavailable for screening[@CD004773-bbs2-0033]MethodsRCTParticipantsNumber of participants (N): 70 participantsInterventions1. Itraconazole 200 mg daily\
2. PlaceboOutcomes1. Treatment discontinuation\
2. Adverse eventsNotesFull text unavailable for screening

AA, SJ, and IEW planned and drafted the protocol, SJ and AA screened and extracted all data, SJ AA and IEW performed all analyses and GRADEd the outcomes.

AA and SJ drafted the final review. IEW commented on the final review.

GM and GR reviewed and edited the protocol, assisted with methodological and clinical queries, and commented on the final review.

Internal sources {#CD004773-sec2-0016}
================

Liverpool School of Tropical Medicine, UK.
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Department for International Development, UK.Grant: 5242

AA has no known conflicts of interest. SJ has no known conflicts of interest. GR has no known conflicts of interest. GM has no known conflicts of interest. IEW has no known conflicts of interest.

[^1]: Editorial Group: Cochrane Infectious Diseases Group.

[^2]: ^a^Not downgraded for inconsistency. I² statistic = 39% ^b^Downgraded two for indirectness. Participants in most of the included studies did not receive current standard ART regimens, nor did they receive them in a time period consistent with current practice. ^c^Not downgraded for imprecision as narrow CIs around absolute risk ^d^Downgraded by one for indirectness. In the largest study, which contributed 47.2% to the pooled estimate of effect, participants received current standard of care in type and time from diagnosis to ART ([@CD004773-bbs2-0004]). ^e^Not downgraded for imprecision; although there were few events, CIs around absolute risk were narrow, containing only clinically appreciable benefit ^f^Downgraded by one for indirectness. Most trials were unclear in how they attributed death to cryptococcal disease. In the largest study, which contributed 68.8% to the pooled estimate of effect, participants received current standard of care in type and time from diagnosis to ART ([@CD004773-bbs2-0004]). ^g^Downgraded one for inconsistency. Clinical heterogeneity in how clinical resistance was defined ^h^Downgrade one for imprecision. Few events in intervention and control groups. ^i^Downgraded one for indirectness. Surveillance sampling did not directly relate to clinical disease. ^j^Downgraded one for imprecision. Broad CIs around absolute risk contained clinically appreciable harm and no appreciable effect. ^k^Downgraded one for indirectness. Studies did not clearly define grading of serious adverse events. ^l^Downgraded one for inconsistency. Unexplained heterogeneity of I² statistic = 64%.

[^3]: Abbreviations: NR: not reported; ART: antiretroviral therapy; CTX: co‐trimoxazole; CD4: cluster of differentiation 4; IQR: interquartile range; +ve: positive; ‐ve: negative.

[^4]: \*Full details of definition of clinical disease available in [Characteristics of included studies](#CD004773-sec2-0018){ref-type="sec"}

[^5]: \*Itraconazole received, cross resistance to fluconazole reported.

[^6]: ^a^We defined this as the number of participants who had to discontinue the study medication because of the need to take other medication that interfered with itraconazole serum levels.

[^7]: Abbreviations: CD4: cluster of differentiation 4; OPC: oropharyngeal candidiasis; EC: oesophageal candidiasis.
